

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 239/42, 239/46, 401/04, 403/04, 405/04, A61K 31/505	A1	(11) International Publication Number: WO 97/44326 (43) International Publication Date: 27 November 1997 (27.11.97)
(21) International Application Number: PCT/EP97/02454 (22) International Filing Date: 14 May 1997 (14.05.97) (30) Priority Data: 60/018,218 23 May 1996 (23.05.96) US 60/040,377 10 March 1997 (10.03.97) US (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basle (CH). (72) Inventors: BERGER, Jacob; 12135 Dawn Lane, Los Altos Hills, CA 94022 (US). FLIPPIN, Lee, Allen; 17659 Skyline Boulevard, Woodside, CA 94062 (US). GREENHOUSE, Robert; 7173 Arbeau Drive, Newark, CA 94560 (US). JAIME-FIGUEROA, Saul; 4907 Knowlson Terrace, Fremont, CA 94555 (US). LIU, Yanzhou; 3154 Mauricia Avenue, Santa Clara, CA 95051 (US). MILLER, Aubry, Kern; 448 Cypress Avenue, Half Moon Bay, CA 94019 (US). PUTMAN, David, George; 18693 McFarland Avenue, Saratoga, CA 95070 (US). WEINHARDT, Klaus, Kurt; 1042 Colorado Avenue, Palo Alto, CA 94303 (US). ZHAO, Shu-Hai; 426 Ositos Avenue, Sunnyvale, CA 94086 (US).	(74) Agent: BRAUN, Axel; Grenzacherstrasse 124, CH-4070 Basle (CH). (81) Designated States: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR, YU, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: ARYL PYRIMIDINE DERIVATIVES (57) Abstract The present invention is directed to pyrimidine derivatives, and pharmaceutically acceptable salts and <i>N</i> -oxides thereof, which exhibit useful pharmacological properties, in particular use as selective 5HT _{2B} -antagonists, their preparation, pharmaceutical compositions comprising them and their use in the treatment of various diseases, especially migraine. The invention is also directed to formulations and methods for treatment.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ARYL PYRIMIDINE DERIVATIVES

The present invention relates to aryl pyrimidine derivatives, and pharmaceutically acceptable salts and
5 N-oxides thereof, which exhibit useful pharmacological properties, including utility as selective 5HT_{2B}-antagonists. The invention is also directed to formulations thereof and their use for the treatment of diseases.

10 Serotonin, a neurotransmitter with mixed and complex pharmacological characteristics, was first discovered in 1948, and subsequently has been the subject of substantial research. Serotonin, also referred to as 5-hydroxy-tryptamine (5-HT), acts both centrally and peripherally on
15 discrete 5-HT receptors. Currently, fourteen subtypes of serotonin receptor are recognized and delineated into seven families, 5-HT₁ to 5-HT₇. Within the 5-HT₂ family, 5-HT_{2A}, 5-HT_{2B} and 5-HT_{2C} subtypes are known to exist. These subtypes share sequence homology and display similarities in
20 their specificity for a wide range of ligands. The nomenclature and classification of 5-HT receptors has been reviewed recently by Martin and Humphrey, *Neuropharm.*, 33, 261-273 (1994) and Hoyer et al., *Pharm. Rev.*, 46, 157-203 (1994) and Hoyer et al., *Pharm. Rev.*, 46, 157-203 (1994).

25 5-HT_{2B} receptors, initially termed 5-HT_{2F} or serotonin-like receptor, were first characterized in rat isolated stomach fundus [Clineschmidt et al. (1985), *J. Pharmacol. Exp. Ther.*, 235, 696-708; Cohen and Wittenauer, (1987), *J. Cardiovasc. Pharmacol.*, 10, 176-181].

- 2 -

The 5-HT_{2C} receptor, first characterized as a 5-HT_{1C} subtype [Pazos et al. (1984), *Eur. J. Pharmacol.*, 106, 539-546] and subsequently recognized as belonging to the 5-HT₂ receptor family [Pritchett et al. (1988), *EMBO J.*, 7, 4135-4140], is widely distributed in the human brain [Pazos et al. (1987), *Neuroscience*, 21, 97-122]. Current evidence strongly supports a therapeutic role for 5-HT_{2C} receptor antagonists in treating anxiety (e.g., generalized anxiety disorder, panic disorder and obsessive compulsive disorder), alcoholism and addiction to other drugs of abuse, depression, migraine, sleep disorders, feeding disorders (e.g., anorexia nervosa) and priapism [Kennett (1993), *Curr. Opin. Invest. Drugs*, 2, 317-362]. Because of the similarities in the pharmacology of ligand interactions at 5-HT_{2C} and 5-HT_{2B} receptors many of the therapeutic targets that have been proposed for 5-HT_{2C} receptor antagonists are also targets for 5-HT_{2B} receptor antagonists. In particular, several clinical observations suggest a therapeutic role for 5-HT_{2B} receptor antagonists in the prevention of migraine, in that mobilization of 5-HT into the plasma may be a precipitating factor in migraine. Additionally, non-selective 5-HT_{2B} receptor agonists provoke migraine attacks in susceptible individuals, and non-selective 5-HT_{2B} receptor antagonists are effective in preventing the onset of migraine [Kalkman (1994), *Life Sciences*, 54, 641-644].

Thus, it is clear that selective 5-HT_{2B} receptor antagonists will offer distinct therapeutic advantages collectively in efficacy, rapidity of onset and absence of side effects. In addition, such agents are expected to be useful in the treatment of hypertension [Watts et al., *J. Pharm. Exp. Ther.*, 277, 1056-1059 (1995)].


Numerous aryl substituted pyrimidine compounds have been exemplified in the chemical and patent literature. For example, Budesinsky et al., *Collection Czechoslov. Chem.*

Commun., 26, 2865-2870 (1961), disclose 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine as an intermediate useful in the preparation of antibacterial compounds. Other pyrimidine derivatives are described in Mariella et al., *J. Org. Chem.*, 5 25, 647-648 (1960); Zagulyaeva et al., *Izv. Sib. Otd. Akad. Nauk SSSR, Ser. Khim. Nauk*, 4, 27-31 (1990); Essawy et al., *Egypt. J. Chem.*, 37(4), 423-31 (1994); U.S. Patents Nos. 4,543,248, 4,619,933, 4,665,077, 5,002,951, 5,147,876 and 5,223,505, and European Patent Publication No. [EP] 459 830.

10

One aspect of the invention concerns compounds represented by formula I:

15



I

20 wherein:

R^1 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl, optionally substituted phenyl, optionally substituted phenyl lower alkyl, $-NR^6R^7$, $-CO_2R^8$, or $-O(CH_2)_nR^9$, in which

25

n is 1, 2, or 3;

R^6 and R^7 are independently hydrogen or lower alkyl;

R^8 is hydrogen or lower alkyl; and

R^9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;

30

R^2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl;

R^3 is optionally substituted aryl;

R^4 is hydrogen, lower alkyl, optionally substituted phenyl-lower alkyl, hydroxy lower alkyl, acyl, $-(CH_2)_mNR^6R^7$, or $-SO_2R^{10}$; in which

35

- 4 -

m is an integer of 1-6;
and
R¹⁰ is lower alkyl; and
R⁵ is hydrogen or lower alkyl;
5 provided that:
when R³ is naphthyl, pyridyl, thienyl, indol-1-yl,
2,3-dihydroindol-1-yl, or furanyl, and R², R⁴ and
R⁵ are all hydrogen, R¹ is not methyl;
when R³ is phenyl or naphthyl, R¹ is not -NR⁶R⁷;
10 when R³ is naphthyl, R¹ is not phenyl; and
when R³ is 1,2,3,4-tetrahydroquinolinyl, R⁴ and R⁵ are
hydrogen;
and the pharmaceutically acceptable salts and N-oxides
thereof.

15

In another aspect, the invention relates to
pharmaceutical compositions containing a therapeutically
effective amount of a compound of formula I, or a
pharmaceutically acceptable salt or N-oxide thereof, in
20 admixture with one or more pharmaceutically acceptable,
non-toxic carriers.

In yet another aspect, the invention relates to a
method for treating a mammal having a disease state which is
25 alleviable by treatment with a 5HT_{2B} antagonist, by
administering to a mammal in need thereof a therapeutically
effective amount of a compound of formula I, or a
pharmaceutically acceptable salt or N-oxide thereof.

30 The use of a compound of formula I, a pharmaceutically
acceptable salt or N-oxide thereof for the preparation of a
medicament for the treatment of a disease state which is
alleviable by treatment with a 5HT_{2B} antagonist is a further
object of the present invention.

35

The following definitions are used throughout the description of the present invention:

"Alkyl" means a branched or unbranched saturated
5 hydrocarbon chain containing 1 to 12 carbon atoms, such as methyl, ethyl, propyl, tert-butyl, n-hexyl, n-dodecyl, and the like.

"Alkenyl" refers to an unsaturated monovalent
10 hydrocarbon radical of 1 to 12 carbon atoms. This term is further exemplified by such radicals as vinyl, prop-2-enyl, pent-3-enyl, hex-5-enyl, oct-2-enyl, and the like.

"Cycloalkyl" means a monovalent saturated carbocyclic
15 radical containing no unsaturation and having from three to eight carbon atoms, e.g., cyclopropyl, 2-methylcyclopropyl, cyclobutyl, 3-ethylcyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl.

20 "Lower alkyl" means a branched or unbranched saturated hydrocarbon chain containing 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, tert-butyl, butyl, n-hexyl and the like, unless otherwise indicated.

25 "Lower alkenyl" refers to an unsaturated monovalent hydrocarbon radical of one to six carbon atoms. This term is further exemplified by such radicals as vinyl, prop-2-enyl, pent-3-enyl, and hex-5-enyl.

30 "Cycloalkyl lower alkyl" as defined herein means cycloalkyl as defined above attached to a lower alkyl radical as defined above, for example e.g., cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl,
35 cycloheptylmethyl, cyclooctylmethyl, and the like.

- 6 -

"Phenyl lower alkyl" means phenyl attached to a lower alkyl radical as defined above, for example phenylmethyl (benzyl), phenylethyl, phenylpropyl, and the like.

5 "Fluoroalkyl" means alkyl as defined above substituted by 1 to 5 fluorine atoms in any position, for example trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoro-n-propyl, 1-fluoro-n-butyl, 1,2-difluoro-3-methylpentane, 1-fluoro-octane, and the like.

10

"Lower fluoroalkyl" means lower alkyl as defined above substituted by 1 to 5 fluorine atoms in any position, for example trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoro-n-propyl, 1-fluoro-n-butyl, 1,2-difluoro-3-methylpentane, 15 and the like.

"Acyl" refers to the group $-C(O)-R'$, where R' is lower alkyl as herein defined.

20

"Lower alkoxy" means the group $-O-R'$ wherein R' is lower alkyl as herein defined. Likewise, "lower thioalkoxy" denotes the group $-S-R'$.

"Hydroxyalkyl" means the group alkyl as defined above substituted by 1, 2 or 3 hydroxy groups, for example 25 hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 1-hydroxyisopropyl, 2-hydroxyisopropyl, 1,2-dihydroxyisopropyl, 1-hydroxybutyl, 1,3-dihydroxybutyl, and the like. Similarly, "hydroxy lower alkyl" means the group 30 lower alkyl as defined above substituted by 1, 2 or 3 hydroxy groups.


"Halo" denotes fluoro, chloro, bromo, or iodo, unless otherwise indicated.

35

- 7 -


"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted phenyl" or "optionally substituted aryl" means that phenyl or aryl may or may not be substituted with a substituent selected from the group consisting of lower alkyl, lower alkoxy, hydroxy, nitro, lower fluoroalkyl, and halo, and encompasses unsubstituted phenyl and unsubstituted aryl and all possible isomeric phenyl and aryl radicals that are mono, di or trisubstituted.

The term "aryl" as used herein means a monocyclic aromatic ring, or a 9 to 14 membered bicyclic or tricyclic ring system in which at least one ring is aromatic in nature, and includes carbocycles, and heterocycles having one or two heteroatoms chosen from nitrogen, oxygen, and sulfur. Examples of aryl groups include, but are not limited to, phenyl, thiophene, naphthalene, anthracene, phenanthrene, quinoline, isoquinoline, 1,2,3,4-tetrahydroquinoline, indole, 2,3-dihydroindole, 1H-benzo[b]azepine, 2,3,4,5-tetrahydro-1H-benzo[b]azepine, 2H-benzo[1,4]oxazine, 3,4-dihydro-2H-benzo[1,4]oxazine, 1H,3H-benzo[de]isochromene, 6,7,8,9-tetrahydro-5-oxa-9-benzocycloheptane, 2,3-dihydro-1,4-benzodioxane, and the like. More specifically, the term aryl includes structures of the formula:




e.g., naphth-1-yl and naphth-2-yl, and derivatives thereof;

- 8 -




5 e.g., quinolin-2-yl, quinolin-4-yl, quinolin-8-yl, and the like, and derivatives thereof;

10




e.g., isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-8-yl, and the like, and derivatives thereof;

15




20 e.g., 1,2,3,4-tetrahydroquinolin-1-yl, 1,2,3,4-tetrahydroquinolin-5-yl, and derivatives thereof;

25



e.g., 3,4-dihydro-2H-benzo[1,4]oxazin-1-yl, 3,4-dihydro-2H-benzo[1,4]oxazin-5-yl, and derivatives thereof;


30




- 9 -

where the dotted line represents an optional double bond,
e.g., indol-1-yl, 1H-indol-4-yl, 2,3-dihydroindol-1-yl, and
derivatives thereof;

5




e.g., 2,3,4,5-tetrahydro-1H-benzo[b]azepine, and derivatives
10 thereof;



15

e.g., 7,8,-dihydro-6H-5-oxa-9-aza-benzocyclohepten-9-yl,
7,8,-dihydro-6H-5-oxa-9-aza-benzocyclohepten-4-yl, and
derivatives thereof;

20



e.g., benzo-1,4-dioxane, and derivatives thereof.

25

The terms "inert organic solvent" or "inert solvent"
mean a solvent inert under the conditions of the reaction
being described in conjunction therewith [including, for
example, benzene, toluene, acetonitrile, tetrahydrofuran
30 ("THF"), dimethylformamide ("DMF"), chloroform ("CHCl₃"),
methylene chloride (or dichloromethane or "CH₂Cl₂"), diethyl
ether, ethyl acetate, acetone, methylethyl ketone, methanol,
ethanol, propanol, isopropanol, tert-butanol, dioxane,
pyridine, and the like]. Unless specified to the contrary,
35 the solvents used in the reactions of the present invention
are inert solvents.

"Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically
5 or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid,
10 maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

15 "N-oxide" refers to the stable amine oxide formed at one of the pyrimidine nitrogen atoms.

The term "treatment" as used herein covers any treatment of a disease in a mammal, particularly a human,
20 and includes:

(i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;

25 (ii) inhibiting the disease, i.e., arresting its development; or

(iii) relieving the disease, i.e., causing regression of the disease.


30 The term "therapeutically effective amount" refers to that amount of a compound of formula I that is sufficient to effect treatment, as defined above, when administered to a mammal in need of such treatment. The therapeutically effective amount will vary depending on the subject and
35 disease state being treated, the severity of the affliction

- 11 -

and the manner of administration, and may be determined routinely by one of ordinary skill in the art.

The term "disease state which is alleviable by treatment with a 5HT_{2B} antagonist" as used herein is intended to cover all disease states which are generally acknowledged in the art to be usefully treated with compounds having affinity for 5HT_{2B} receptors in general, and those disease states which have been found to be usefully treated by the specific compounds of our invention, the compounds of formula I. Such disease states include, but are not limited to, anxiety (e.g., generalized anxiety disorder, panic disorder and obsessive compulsive disorder), alcoholism and addiction to other drugs of abuse, depression, migraine, hypertension, sleep disorders, feeding disorders (e.g., anorexia nervosa) and priapism.

The compounds of formula I, illustrated below, will be named using the indicated numbering system:



A compound of formula I wherein R¹ is isopropyl, R², R⁴ and R⁵ are hydrogen, and R³ is 1-naphthyl, is named:

2-amino-6-isopropyl-4-(naphth-1-yl)-pyrimidine.

A compound of formula I wherein R¹ is isopropyl, R², R⁴ and R⁵ are hydrogen, and R³ is 1H-indol-4-yl, is named:

2-amino-4-(1H-indol-4-yl)-6-isopropylpyrimidine.

A compound of formula I wherein R¹ is methyl, R² and R⁴ are hydrogen, R⁵ is methyl, and R³ is 1,2,3,4-tetrahydroquinolin-1-yl, is named:

5

6-methyl-2-(methylamino)-4-(1,2,3,4-tetrahydroquinolin-1-yl)-pyrimidine.

A 1-N-oxide of a compound of formula I wherein R¹ is
10 chloro, R² is methyl, R⁴ and R⁵ are hydrogen, and R³ is 4-methoxyphenyl, is named:

2-amino-6-chloro-4-(4-methoxyphenyl)-5-methylpyrimidine-1-N-oxide.

15

Among the family of compounds of the present invention, one preferred category includes the compounds of formula I in which R⁴ and R⁵ are hydrogen or lower alkyl. Within this category a preferred group includes the compounds where R¹
20 is lower alkyl, fluoroalkyl or hydroxyalkyl and R³ is optionally substituted aryl, especially where R³ is optionally substituted 1-naphthyl or indol-4-yl, or a pharmaceutically acceptable salt or N-oxide thereof.

25 Specifically preferred compounds are:

2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine;
2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine
2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-

30 1-N-oxide;

2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine;

2-amino-6-(tert-butyl)-4-(4-fluoronaphth-1-yl)-pyrimidine;

35 2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine;

2-amino-4-(1H-indol-4-yl)-6-methylpyrimidine;

- 13 -

2-amino-4-(4-fluoronaphth-1-yl)-6-(1-fluoro-1-methyl-ethyl)-pyrimidine; and

2-amino-4-(4-fluoronaphth-1-yl)-6-(1-hydroxy-1-methyl-ethyl)-pyrimidine;

5 2-amino-4-(4,6-difluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine;

2-methylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine;

10 2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine.

A further preferred group of compounds of the present invention are compounds of formula I in which R⁴ and R⁵ are hydrogen or lower alkyl, R¹ is lower alkyl and R³ is
15 optionally substituted indole, e.g. 2-amino-4-(1H-indol-4-yl)-6-methylpyrimidine or a pharmaceutically acceptable salt or N-oxide thereof.

The following methods can be used for the preparation
20 of compounds of formula I:


One such method starts with intermediates of formula (4), the preparation of which is shown in Reaction Scheme I below.

25

- 14 -

REACTION SCHEME I

5



25

where R is lower alkyl, and R^1 and R^2 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl.

30

The starting ketoester of formula (1) may be obtained commercially, for example from Aldrich Chemical Co., Inc., or may be prepared according to methods well known in the art. The compounds of formula (2) are commercially available, or may be prepared according to methods well

35

known in the art.


- 15 -

To prepare compounds of formula (3), a ketoester of formula (1) is treated with an excess of a guanidine derivative of formula (2) in a protic solvent, preferably ethanol, at reflux temperature for about 6-24 hours, preferably about 16 hours. The product of formula (3), a 2-amino-4-hydroxypyrimidine derivative, is isolated by conventional means, and preferably reacted in the next step with no further purification.

The 2-amino-4-hydroxypyrimidine derivative of formula (3) is converted to the corresponding 4-chloro compound of formula (4) by reacting a compound of formula (3) with a chlorinating agent, preferably phosphorous oxychloride, preferably in the absence of solvent. The reaction is conducted at reflux temperature for about 30 minutes to 8 hours, preferably about 2 hours. The product of formula (4), a 2-amino-4-chloropyrimidine derivative, is isolated by conventional means, and is preferably recrystallized before further reaction.

One method of converting a compound of formula (4) to a compound of formula I is shown below in reaction scheme II.

REACTION SCHEME II:





where R^1 , R^2 and R^3 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl.

A 2-amino-4-chloropyrimidine derivative of formula (4) is reacted with a boronic acid derivative of formula (5) in an aqueous solvent, preferably a mixture of ethanol, water and dimethoxyethane, containing a palladium catalyst, preferably palladium tetrakis(triphenylphosphine), and an inorganic base, preferably sodium carbonate. The reaction is preferably carried out at the reflux temperature of the solvent, preferably about 80-90°C, for about 5-30 hours, preferably about 14 hours. The product of formula I is isolated by conventional means, and preferably purified by recrystallization.

An alternative method of converting a compound of formula (4) to a compound of formula I is shown below in Reaction Scheme III.

REACTION SCHEME III:




where R is lower alkyl, R^1 , R^2 and R^3 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl.

- 17 -

The bromoaryl derivative of formula (6) is reacted with a strong base, for example a lower alkyl lithium, preferably n-butyl lithium. The reaction is carried out in an ethereal solvent (for example, diethyl ether, dimethoxyethane, dioxane or tetrahydrofuran, preferably tetrahydrofuran), at a temperature of about -50 to -150°C, preferably about -95°C, for about 5-30 minutes, after which time about 1 equivalent of a trialkoxyborane, preferably trimethoxyborane, is added, and the mixture allowed to warm to room temperature. The product of formula (7), a dimethoxyborane complex, is isolated by removal of solvent, and used in the next reaction with no further purification.

A 2-amino-4-chloropyrimidine derivative of formula (4) is reacted with the boron complex of formula (7) obtained above in an inert solvent, preferably an aromatic solvent, most preferably toluene, containing a palladium catalyst, preferably palladium tetrakis(triphenylphosphine), and an aqueous inorganic base, preferably sodium carbonate/water. The reaction is preferably carried out at the reflux temperature of the solvent, preferably about 80-90°C, for about 10 minutes to 10 hours, preferably about 1 hour. The product of formula I is isolated and purified by conventional means, preferably purified by chromatography.


An alternative method is available for converting a compound of formula (4) to a compound of formula I, in which R^3 is a bicyclic ring system containing N as the point of attachment to the pyrimidine nucleus, i.e., R^3 is represented as:



in which n is 0, 1 or 2, Y is CH_2 , O , S or NH , and the rings are optionally substituted as defined above. This method is shown below in Reaction Scheme IV.

5

REACTION SCHEME IV:



in which n is 0, 1 or 2, Y is CH_2 , O , S or NH , and R^1 , R^2 , R^4 and R^5 are as defined with respect to formula I.

A 2-amino-4-chloropyrimidine derivative of formula (4) is reacted with the compound of formula (8) in a mixture of water and a strong acid, preferably sulfuric acid, as a solvent. The reaction is preferably carried out at a temperature of about 100°C , for about 20 minutes to 10 hours, preferably about 2 hours. The product of formula I is isolated by conventional means, and preferably purified by recrystallization.


Alternatively, the compounds of formula (4) and (8) are reacted together in a polar solvent, preferably dimethylformamide. The reaction is preferably carried out at a temperature of about $70\text{--}90^\circ\text{C}$, for about 12-72 hours, preferably about 24 hours. The product of formula I is isolated by conventional means, and preferably purified by chromatography.

35

Compounds of formula I can also be prepared starting from acylaryl derivatives of formula (9), as shown below in Reaction Scheme V.

5

REACTION SCHEME V:



where R is lower alkyl, R⁴ and R⁵ are hydrogen or lower alkyl, and R¹, R² and R³ are as defined with respect to formula I.

An acyl aryl derivative of formula (9) may be obtained commercially, for example from Aldrich Chemical Co., Inc., or may be prepared according to methods well known in the art, for example, Friedel-Crafts reaction. In general, an aryl derivative of formula R³H is reacted with a carboxylic acid derivative, preferably acetic anhydride in the presence of Lewis acid, for example aluminum chloride. The reaction is carried out at a temperature of about -20° to 20°C, preferably 0°C for about 5 minutes to 3 hours, preferably 20 minutes. The acylaryl derivative product of formula (9) is isolated by conventional means, and preferably purified by chromatography.

35

- 20 -



An acylaryl derivative of formula (9) is reacted with a large excess of an ester of formula (10) in the presence of a strong base, preferably sodium hydride. The reaction is preferably carried out at a temperature of about 80°C, until the compound of formula (9) is consumed. The dione of formula (11) is isolated by conventional means, and preferably purified by chromatography.

Preparation of Compounds of Formula I

The dione of formula (11) is reacted with the compound of formula (2), preferably in the absence of solvent. The reaction is carried out at a temperature of about 100-180°C, preferably at about 150°C, for about 1-10 hours, preferably about 5 hours. The product of formula I is isolated by conventional means, and preferably purified by chromatography.

An alternative method of preparation of compounds of formula I where R¹ is hydrogen from acylaryl derivatives of formula (9) is shown below in Reaction Scheme VI.

REACTION SCHEME VI:



35 where R⁴ and R⁵ are hydrogen or lower alkyl, and R² and R³ are as defined with respect to formula I.

An acylaryl derivative of formula (9) is reacted with tert-butyloxybis(dimethylamino)methane (Bredereck's reagent) in a protic solvent, preferably ethanol. The reaction is preferably carried out at a temperature of about 80°C, for about 12 hours to 5 days, preferably about 2 days. The compound of formula (13) is isolated by conventional means, and preferably used in the next reaction with no further purification.


10

The enone of formula (13) is reacted with the compound of formula (2), preferably in the absence of solvent. The reaction is carried out at a temperature of about 100-180°C, preferably at about 120°C, for about 5-24 hours, preferably about 14 hours. The product of formula I is isolated by conventional means, and preferably purified by recrystallization.

20 Another method of preparation of compounds of formula I is from intermediates of formula (16), the preparation of which is shown in Reaction Scheme VII below.

- 22 -

REACTION SCHEME VII:



where R is lower alkyl, and R¹, and R² are as defined with respect to formula I.

20

The starting ketoester of formula (1) may be obtained commercially, for example from Aldrich Chemical Co., Inc., or may be prepared according to methods well known in the art. The compounds of formula (14) are commercially available or
25 may be prepared according to methods well known in the art.

To prepare compounds of formula (15), a ketoester of formula (1) is treated with about 2 molar equivalents of an isothioureia derivative of formula (14) in an aqueous
30 solution containing an excess of an inorganic base, preferably sodium carbonate. The reaction is carried out at a temperature range from about 5°C to 60°C, preferably at about 25°C, for about 10 to 100 hours, preferably 60 hours. The product of formula (15), a 4-hydroxy-2-methylthio-
35 pyrimidine derivative, is isolated by conventional means and

- 23 -


preferably reacted in the next step with no further purification.

5 The 4-hydroxy-2-methylthiopyrimidine derivative of
formula (15) is converted to the corresponding 4-chloro
compound of formula (16) under conditions similar to that
shown above for the preparation of compounds of formula (4)
in Reaction Scheme I. The product of formula (16), a
4-chloro-2-methylthiopyrimidine derivative is isolated by
10 conventional means.

One method of converting a compound of formula (16) to
a compound of formula I is shown below in Reaction Scheme
VIII.

15

REACTION SCHEME VIII:



where R^1 , R^2 and R^3 are as defined with respect of formula I.

In a first step 1 compounds of formula (17) can be prepared as follows:

- 25 -

A 6-(lower alkyl or lower alkoxy)-2-methylthio-pyrimidine compound of formula (16) in an anhydrous ethereal solvent, preferably tetrahydrofuran, is reacted with an excess of a hindered base, preferably lithium diisopropyl-
5 amide, in an anhydrous ethereal solvent, preferably tetrahydrofuran at a temperature range of about -90°C to 10°C, preferably at about -70°C, for about 30 minutes. An excess of a bromoaryl derivative of formula (6) is added and the reaction mixture allowed to warm to ambient temperature.
10 The product of formula (17), a 2-methylthiopyrimidine compound of formula (17) is then isolated and purified by conventional means, preferably by chromatography.

Alternatively, using the method shown in Reaction
15 Scheme III, a compound of formula (16) can be reacted with a compound of formula (7) to give a compound of formula (17).

In a second step 2 compounds of formula (18) can be prepared as follows:

20

A 2-methylthiopyrimidine derivative of formula (17) is reacted with about 1-4 molar equivalents, preferably about 2 molar equivalents, of a strong oxidizing agent, for example meta-chloroperbenzoic acid. The reaction is carried out in
25 an inert solvent, preferably methylene chloride, in a temperature range from about 0°C to 50°C, preferably about 25°C, for about 1 to 30 hours, preferably about 16 hours. The product of formula (18), a 2-methylsulfonylpyrimidine derivative, is isolated by conventional means.

30

In a third step 3 compounds of formula I can be prepared as follows:

A 2-methylsulfonylpyrimidine derivative of formula (18)
35 is reacted with an excess of a primary or secondary amine in a suitable solvent, for example, ethanol. The reaction is

- 26 -


carried out in a temperature range of about 10° to 100°C, preferably 45°C, for about 1 to 10 hours, preferably 6 hours. The product, a compound of formula I, is isolated and purified by conventional means.

5

Miscellaneous routes for the preparation of to compounds of formula I are shown in Reaction Scheme IX below:

- 27 -

REACTION SCHEME IX:



35 where R⁴ and R⁵ are hydrogen or lower alkyl, and R² and R³ are as defined with respect to formula I.

- 28 -

Compounds of formula I where R^1 is chloro can be made from compounds of formula I where R^1 is hydroxy in the same manner as shown in Reaction Scheme I, step 2, above.

5 Alternatively, compounds of formula I where R^1 is chloro can be made from compounds of formula (4) where R^1 is chloro (i.e., 4,6-dichloro-pyrimidine derivatives) by reacting the dichloro derivative in the same manner as shown
10 in Reaction Schemes II or III.

A compound of formula I where R^1 is chloro is reacted with a primary or secondary amine of formula R^6R^7NH , where R^6 is hydrogen or lower alkyl and R^7 is lower alkyl, in a
15 high-boiling protic solvent, preferably ethylene glycol. The reaction is preferably carried out at a temperature of about $100^\circ C$, for about 12 hours to 5 days, preferably about 2 days. The compound of formula I where R^1 is $-NR^6R^7$ is isolated by conventional means.


20 A compound of formula I where R^1 is chloro is catalytically reduced with hydrogen in the presence of a palladium or platinum catalyst, preferably palladium on carbon support. The reaction is carried out in a protic
25 solvent, preferably methanol or ethanol, in the presence of a strong base, preferably aqueous sodium hydroxide. The reaction is preferably carried out at a temperature of about $10-40^\circ C$, preferably about room temperature, at about 1 atmosphere pressure until reduction is complete, about 1
30 hour. The compound of formula I where R^1 is hydrogen is isolated by conventional means.

The preparation of compounds of formula I where R^1 is thioalkoxy is shown below in Reaction Scheme X.

35

- 29 -

REACTION SCHEME X:



where R^4 and R^5 are hydrogen or lower alkyl, and R^2 and R^3 are as defined with respect to formula I.

An acylaryl derivative of formula (9), which may be obtained commercially, for example from Aldrich Chemical Co., Inc., or may be prepared according to methods well known in the art, is mixed with carbon disulfide in an aprotic solvent, for example diethyl ether, benzene, toluene, preferably diethyl ether, in the presence of a strong base, preferably potassium tert-butyloxyde, at a temperature of about 10-12°C. The reaction mixture is allowed to warm to room temperature, then recooled to about 10-12°C, at which point 2 molar equivalents of methyl iodide is added dropwise. The mixture is maintained at a temperature of about 10-80°C, preferably about room temperature, for about 5-24 hours, preferably about 16 hours. The bis-methylsulfanyl compound of formula (19) is


isolated by conventional means, and preferably purified by crystallization.

The compound of formula (19) is reacted with the
5 compound of formula (2) in the presence of a strong base, preferably sodium hydride, in a polar solvent, preferably dimethylformamide. The reaction is carried out at room temperature for about 1 hour, then at about 100-180°C, preferably at about 150°C, for about 1-10 hours, preferably
10 about 5 hours. The product of formula I is isolated by conventional means, and preferably purified by chromatography.

The compound of formula (19) is reacted with the
15 compound of formula (2) in the presence of a strong base, preferably sodium hydride, in a polar solvent, preferably dimethylformamide. The reaction is carried out at room temperature for about 1 hour, then at about 100-180°C, preferably at about 150°C, for about 1-10 hours, preferably
20 about 5 hours. The product of formula I is isolated by conventional means, and preferably purified by chromatography.

The preparation of N-oxides of compounds of formula I
25 is shown below in Reaction Scheme XI.

REACTION SCHEME XI:



- 31 -


where R^1 , R^2 , R^3 , R^4 and R^5 are as defined with respect to formula I.

A compound of formula I is reacted with an oxidizing agent, preferably m-chloroperbenzoic acid, in an inert solvent, preferably chloroform or methylene dichloride. The reaction is preferably carried out at a temperature of about 30-60°C, preferably about 40°C, for about 10 minutes to 2 hours, preferably about 30 minutes. The N-oxide of the compound of formula I is isolated by conventional means.

The position of the N-oxidation varies depending upon the steric hindrance of the R^1 group. For example, where R^1 is methyl, N-oxidation occurs almost exclusively at the 1-position (formula Ia). However, as the R^1 group increases in size, increasing amounts of the 3-N-oxide (formula Ib) are seen. For example, where R^1 is tert-butyl, most of the oxidation is directed toward the 3-position. For oxidations where a mixture of N-oxides are obtained, the 1-N-oxides and 3-N-oxides can be separated by chromatography, or by selective crystallization from a suitable solvent, for example from a mixture of ethanol/ether.

The preparation of compounds of formula I where R^1 is hydroxyalkyl or alkenyl from N-oxides of formula I is shown below in Reaction Scheme XII.

REACTION SCHEME XII:



where in formulae Ia and Ib R^1 is alkyl, and in formula I R^1 is hydroxyalkyl or alkenyl, and R^2 , R^3 , R^4 and R^5 are as with respect to formula I.

20 An N-oxide of formula I where R^1 is alkyl is reacted with an excess of a carboxylic anhydride preferably trifluoroacetic anhydride, in an inert solvent, preferably methylene chloride. The reaction is carried out at a temperature of about 5 to 60°C, preferably about 25°C, for about 10 to 60 hours, preferably 48 hours. A mixture of compounds of formula I where R^1 is 6-hydroxyalkyl or 6-alkenyl is obtained, and is separated, isolated and purified by conventional means, preferably by chromatography.

30 The compounds of formula I where R^1 , R^2 and R^3 are as defined above, and R^4 and R^5 are hydrogen may be converted to other compounds of formula I by replacing one or both hydrogens of R^4 and R^5 with other groups:

35 A. For example, a compound of formula I where R^4 is acetyl, may be prepared by reaction with an acylating agent,

- 33 -

- preferably acetic anhydride, optionally in the presence of 4-dimethylaminopyridine. The reaction mixture was carried out at a temperature range of 0° to 100°C, for about 4 hours. A diacetyl product is isolated by conventional means, dissolved in a protic solvent, such as methanol, and treated with sodium bicarbonate for about 1 to 24 hours. The resulting monoacetyl product, a compound of formula I, is isolated and purified by conventional means.
- 10 B. For example, a compound of formula I where R⁴ and R⁵ are methanesulfonyl, may be prepared by reaction with triethyl amine and a sulfonylating agent, preferably methanesulfonyl chloride. The reaction was carried out in an inert organic solvent, such as dichloromethane, at a temperature of about 0°, for about 5 minutes to 3 hours, preferably 30 minutes. The resulting bis-methylsulfonyl product, a compound of formula I, is isolated and purified by conventional means.
- 20 C. For example, a compound of formula I where R⁴ is methanesulfonyl, and R⁵ is hydrogen, may be prepared from the bis-methanesulfonyl product previously described above in (B), under basic conditions, preferably sodium hydroxide. The reaction was carried out in a protic organic solvent, such as methanol, at about room temperature for about 30 minutes to 3 hours, preferably 1 hour. The resulting mono-methanesulfonyl product, a compound of formula I, is isolated and purified by conventional means.
- 30 D. For example, a compound of formula I where R⁴ and R⁵ is hydrogen may be prepared by reaction with phenylisocyanate. The reaction was carried out in an inert organic solvent, preferably benzene, at reflux temperature for about 10 to 60 hours, preferably 48 hours. The resulting urea product, a compound of formula I, is isolated and purified by conventional means.
- 35

- 34 -

E. For example, a compound of formula I where R^4 is 2-(dimethylamino)imino, and R^5 is hydrogen, may be prepared by reaction with a guanidine derivative, such as 1,1-dimethylguanidine, and following the procedures described in reaction scheme I.

Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be taken from the preparations and examples. However, other equivalent separation or isolation procedures could, of course, also be used.

The compounds of formula I are basic, and thus may be converted to a corresponding acid addition salt.

The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained at 0°-50°C. The resulting salt precipitates

spontaneously or may be brought out of solution with a less polar solvent.


The acid addition salts of the compounds of formula I
5 may be converted to the corresponding free bases by
treatment with at least a stoichiometric amount of a
suitable base such as sodium or potassium hydroxide,
potassium carbonate, sodium bicarbonate, ammonia, and the
like.

10

Compounds of formula I can be prepared as follows:

1. Reacting a compound of the formula:

15



20


where R¹ and R² are as defined above and R⁴ and R⁵ are
hydrogen or lower alkyl;

25 with a boronic acid derivative of formula (5), i.e.,
R³B(OH)₂, where R³ is as defined with respect to formula I.

2. Alternatively, a process for preparing compounds of
formula I comprises:

30 reacting a compound of the formula:

35




- 36 -

where R^1 and R^2 are as defined with respect to formula I,
 and R^4 and R^5 are hydrogen or lower alkyl;
 with a boron complex of formula (7), i.e., $R^3B(OCH_3)_2$, where
 R^3 is as defined with respect to formula I.

5


3. Alternatively, a process for preparing compounds of
 formula I comprises:

reacting a compound of the formula:



where R^1 and R^2 are as defined with respect to formula I and
 R^4 and R^5 are hydrogen or lower alkyl;
 with a compound of the formula (8):

20




25 where Y and n are as defined above.

4. Alternatively, a process for preparing compounds of
 formula I comprises:

reacting a compound of the formula:

30




35 where R^1 , R^2 , and R^3 are as defined with respect to
 formula I;

- 37 -

with a compound of the formula $\text{NH}_2\text{C}(\text{:NH})\text{NR}^4\text{R}^5$ (formula (2)),
where R_4 and R_5 are as defined with respect to formula I.

5. Alternatively, a process for preparing compounds of
5 formula I comprises:

reacting a compound of the formula:




where R^2 and R^3 are as defined with respect to formula I;
with a compound of the formula $\text{NH}_2\text{C}(\text{:NH})\text{NR}^4\text{R}^5$ (formula (2)),
where R_4 and R_5 are as defined with respect to formula I.

15

6. Alternatively, a process for preparing compounds of
formula I comprises:

reacting a compound of the formula:

20




25 where R^3 is as defined with respect to formula I
with a compound of the formula $\text{NH}_2\text{C}(\text{:NH})\text{NR}^4\text{R}^5$ (formula (2)),
where R_3 is as defined with respect to formula I.

7. Alternatively, a process for preparing compounds of
30 formula I comprises:

reacting a compound of the formula I where R^1 is chloro:

35




- 38 -

- where R^2 and R^3 are as defined with respect to formula I,
5 and R^4 and R^5 are hydrogen or lower alkyl; with
A) a reducing agent, to give a compound of formula I where
 R^1 is hydrogen; or
B) a secondary amine of formula HNR^6R^7 , where R^6 and R^7
are as defined with respect to formula I, to give a compound
10 of formula I where R^1 is $-NR^6R^7$.

8. Alternatively, a process for preparing compounds of
formula I comprises:

reacting a compound of the formula:

15



20

- where R^1 , R^2 and R^3 are as defined with respect to formula
I, with a secondary amine of formula HNR^4R^5 , where R^4 and R^5
are as defined with respect to formula I, to give a compound
25 of formula I, where R^4 and R^5 are as defined with respect to
formula I.

9. Alternatively, a process for preparing compounds of
formula I where R^1 is hydroxyalkyl or alkenyl comprises:
30 reacting an N-oxide of a compound of formula I where R^1 is
alkyl with a carboxylic anhydride to give a compound of
formula I.

10. Alternatively, a process for preparing compounds of
35 formula I comprises:

reacting a compound of formula I with an oxidizing agent to give an N-oxide of a compound of formula I, or:
reacting a compound of formula I with a strong acid to give a pharmaceutically acceptable salt of a compound of formula
5 I.

The compounds of this invention are selective 5-HT_{2B} receptor antagonists. Affinity for the 5-HT_{2B} receptors was demonstrated using an *in vitro* binding assay utilizing
10 cloned 5-HT_{2B} receptors radiolabelled with [³H]-5HT, as shown in Example 17 *infra*. Selectivity for the 5-HT_{2B} receptor was shown by counter screening at 5-HT_{2A} and 5-HT_{2C} receptors (for details see Example 18, *infra*). Antagonist properties were determined in rat stomach fundus
15 longitudinal muscle (for further details see Example 19, *infra*).

Accordingly, the compounds of this invention are useful for treating diseases which can be ameliorated by blockade
20 of 5-HT_{2B} receptors. Because of the similarities in the pharmacology of ligand interactions at 5-HT_{2C} and 5-HT_{2B} receptors many of the therapeutic targets that have been proposed for 5-HT_{2C} receptor antagonists are also targets for 5-HT_{2B} receptor antagonists. In particular, several
25 clinical observations suggest a therapeutic role for 5-HT_{2B} receptor antagonists in the prevention of migraine, in that mobilization of 5-HT into the plasma is believed to be a precipitating factor in migraine. Additionally, non-selective 5-HT_{2B} receptor agonists provoke migraine attacks
30 in susceptible individuals, and non-selective 5-HT_{2B} receptor antagonists are effective in preventing the onset of migraine [Kalkman, *Life Sciences*, 54, 641-644 (1994)].

Clinical and experimental evidence support a
35 therapeutic role for 5-HT_{2C} receptor antagonists in treating anxiety. The 5-HT_{2C} receptor agonist 1-(3-chlorophenyl)-

- 40 -

piperazine (mCPP) when administered to human volunteers causes anxiety [Charney et al. (1987), *Psychopharmacology*, 92, 14-24]. MCPP also produces anxiogenic effects in rat, social interaction (SI) and elevated X-maze models of anxiety, which effects are blocked by non-selective 5-HT_{2C/2A} receptor antagonists but not by selective 5-HT_{2A} receptor antagonists [Kennett et al. (1989), *Eur. J. Pharmacol.*, 164, 445-454 and Kennett (1993), *supra*]. In addition, non-selective 5-HT_{2C/2A} receptor antagonists by themselves produce anxiolytic effects in the SI and Geller Seifter conflict tests, while selective 5-HT_{2A} receptor antagonists do not share this property. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

15

Furthermore, mCPP when administered to panic disorder patients or obsessive compulsive disorder patients increases levels of panic and/or anxiety [Charney et al. (1987), *supra*., and Zohar et al. (1987), *Arch. Gen. Psychiat.*, 44, 946-951]. Thus, current evidence support the application of selective 5-HT_{2C} receptor antagonists for treating generalized anxiety disorder, panic disorder and obsessive compulsive disorder. These therapeutic targets for 5-HT_{2C} receptor antagonists are equally targets for 5-HT_{2B} receptor antagonists.

25

Anxiolytic activity can be determined experimentally by the art-recognized Crawley and Goodwin two-compartment exploratory model [e.g., see Kilfoil et al. (1989), *Neuropharmacology*, 28(9), 901-905]. In brief, the method measures the extent a compound affects the natural anxiety of mice in a novel, brightly lighted area (for further details see Example 21, *infra*).

30

Clinical and experimental evidence support a therapeutic role for selective 5-HT_{2C} receptor antagonists

35

-41-

in treating chemical dependency. The 5-HT_{2C} receptor agonist mCPP induces a craving for alcohol in abstaining alcoholics [Benkelfat et al. (1991), *Arch. Gen. Psychiat.*, 48, 383]. In contrast, the non-selective 5-HT_{2C/2A} receptor antagonist ritanserin reduces alcohol preference in rats [Meert et al., (1991), *Drug Development Res.* 24, 235-249], while the selective 5-HT_{2A} receptor antagonist ketanserin has no affect on preference for alcohol [Kennett et al., (1992), *J. Psychopharmacol.*, Abstr. A26].

10 Ritanserin also reduces both cocaine and fentanyl preference in rat models of addiction [Meert et al. (1991), *Drug Development Res.* 25, 39-53 and Meert et al., (1991), *Drug Development Res.* 25, 55-66]. Clinical studies show that ritanserin decreases alcohol intake in chronic alcoholics

15 [Monti et al. (1991), *Lancet.* 337, 60] and is useful in patients withdrawing from other drugs of abuse [Sadzot et al. (1989), *Psychopharmacology*, 98, 495-499]. Thus, current evidence support the application of selective 5-HT_{2C} receptor antagonists for treating alcoholism and

20 addiction to other drugs of abuse. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

Ameliorating effects of compounds during withdrawal

25 from drugs of abuse can be determined experimentally by the mouse, withdrawal anxiety test, an accepted assay [Carboni et al. (1988), *Eur. J. Pharmacol.* 151, 159-160]. This procedure utilizes the exploratory model described above to measure the extent a compound ameliorates the symptoms of

30 withdrawal that occur after chronically treating with an addictive substance and then abruptly ceasing the treatments (for further details see Example 22, *infra.*).

Clinical evidence support a therapeutic role for

35 selective 5-HT_{2C} receptor antagonists in treating depression. For example, non-selective 5-HT_{2C/2A} receptor

antagonists show clinical efficacy in treating depression [Murphy (1978), *Brit. J. Pharmacol.*, 5, 81S-85S; Klieser et al. (1988), *Pharmacopsychiat.*, 21, 391-393; and Camara (1991), *Biol. Psychiat.*, 29, 201A]. Furthermore,

5 experimental results suggest that the mechanism by which conventional antidepressant drugs exert their therapeutic efficacy is through adaptive changes in the serotonergic system [Anderson (1983), *Life Sci.*, 32, 1791-1801]. For example, chronic treatment with monamine oxidase inhibitors

10 reduce mCPP-induced/5-HT_{2C} mediated functional responses in a variety of paradigms. Similar effects are exhibited by selective 5-HT reuptake inhibitors. These findings suggest that treatments which enhance extraneuronal 5-HT levels desensitize 5-HT_{2C} receptor function which in turn causes,

15 or contributes to, antidepressant activity ([Kennett (1993), *supra*]. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

20 Clinical evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in treating sleep disorders. The 5-HT_{2C} receptor agonist mCPP when administered to human volunteers reduces total sleep time, sleep efficiency, slow wave sleep (SWS) and rapid eye movement sleep [Lawlor et al.

25 (1991), *Biol. Psychiat.*, 29, 281-286]. In contrast, the non-selective 5-HT_{2C/2A} receptor antagonist ritanserin increases SWS, reduces sleep onset latency and improves subjective sleep quality in healthy volunteers [Idzikowski et al. (1986), *Brain Res.*, 378, 164-168; Idzikowski et al.

30 (1987), *Psychopharmacology*, 93, 416-420; Declerck et al. (1987), *Curr. Therap. Res.*, 41, 427-432; and Adam et al. (1989), *Psychopharmacology*, 99, 219-221]. Thus, given the opposing effects of 5-HT_{2C} receptor stimulation and 5-HT_{2C} receptor antagonism, selective 5-HT_{2C} receptor antagonists

35 could be of particular therapeutic value in treating sleep disorder [Kennett (1993), *supra*]. This therapeutic target

- 43 -

for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

Clinical evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in feeding disorders. Non-specific 5-HT_{2C/2A} receptor antagonists are shown to produce increased appetite and weight gain. Thus, there is some clinical evidence to support the application of selective 5-HT_{2C} receptor antagonists for the treatment of anorexia nervosa. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

Experimental evidence support a therapeutic role for 5-HT_{2C} receptor antagonists in treating priapism. MCPP produces penile erections in rats, which effect is blocked by non-selective 5-HT_{2C/2A} receptor antagonists but not by selective 5-HT_{2A} receptor antagonists [Hoyer (1989), In: Fozard J. (ed.) Peripheral actions of 5-HT, Oxford University Press, Oxford, 72-99]. This therapeutic target for 5-HT_{2C} receptor antagonists is equally a target for 5-HT_{2B} receptor antagonists.

In applying the compounds of this invention to treatment of the above conditions, administration of the active compounds and salts described herein can be via any of the accepted modes of administration, including oral, parenteral and otherwise systemic route of administration. Any pharmaceutically acceptable mode of administration can be used, including solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages, or in sustained or controlled release dosage forms for the prolonged administration of the compound at a predetermined rate. The compositions will typically include a conventional

pharmaceutical carrier or excipient and an active compound of formula I or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.

5

The amount of active compound administered will of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. However, an effective dose for oral, parenteral and otherwise systemic routes of administration is in the range of 0.01-20 mg/kg/day, preferably 0.1-10 mg/kg/day. For an average 70 kg human, this would amount to 0.7-1400 mg per day, or preferably 7-700 mg/day.

15

One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of a compound of formula I for a given disease.

For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, sodium crosscarmellose, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, acetylated triglycerides and the like, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered

may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, 5 sorbitan monolaurate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975. The 10 composition or formulation to be administered will, in any event, contain a quantity of the active compound(s) in an amount effective to alleviate the symptoms of the subject being treated.

15 Dosage forms or compositions containing active ingredient (compounds of formula I or its salts) in the range of 0.25 to 95% with the balance made up from non-toxic carrier may be prepared.

20 For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, sodium crosscarmellose, starch, 25 magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 30 1%-95% active ingredient, more preferably 2-50%, most preferably 5-8%.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or 35 intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid

- 46 -

forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical
5 compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, triethanolamine sodium acetate, etc.

10

A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795.

15

The percentage of active compound contained in such parental compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active
20 ingredient of 0.1% to 10% in solution are employable, and will be higher if the composition is a solid which will be subsequently diluted to the above percentages. Preferably the composition will comprise 0.2-2% of the active agent in solution.

25

In applying the compounds of the invention to treatment of diseases or disorders of the eye which are associated with an abnormally high intraocular pressure, administration may be achieved by any pharmaceutically acceptable mode of
30 administration which provides adequate local concentrations to provide the desired response. These include direct administration to the eye via drops and controlled release inserts or implants, as well as systemic administration as previously described.

35

- 47 -

Drops and solutions applied directly to the eye are typically sterilized aqueous solutions containing 0.1% to 10%, most preferably 0.5% to 1% of the active ingredient, along with suitable buffer, stabilizer, and preservative.

5 The total concentration of solutes should be such that, if possible, the resulting solution is isotonic with the lacrimal fluid (though this is not absolutely necessary) and has an equivalent pH in the range of pH 6-8. Typical preservatives are phenyl mercuric acetate, thimerosal,

10 chlorobutanol, and benzalkonium chloride. Typical buffer systems and salts are based on, for example, citrate, borate or phosphate; suitable stabilizers include glycerin and polysorbate 80. The aqueous solutions are formulated simply by dissolving the solutes in a suitable quantity of water,

15 adjusting the pH to about 6.8-8.0, making a final volume adjustment with additional water, and sterilizing the preparation using methods known to those in the art.

The dosage level of the resulting composition will, of course, depend on the concentration of the drops, the condition of the subject and the individual magnitude of responses to treatment. However, a typical ocular composition could be administered at the rate of about 2-10 drops per day per eye of a 0.5% solution of active

25 ingredient.

The compositions of the present invention may also be formulated for administration in any convenient way by analogy with other topical compositions adapted for use in

30 mammals. These compositions may be presented for use in any conventional manner with the aid of any of a wide variety of pharmaceutical carriers or vehicles. For such topical administration, a pharmaceutically acceptable non-toxic formulation can take the form of semisolid, liquid, or

35 solid, such as, for example, gels, creams, lotions, solutions, suspensions, ointments, powders, or the like. As

- 48 -

an example, the active components may be formulated into a gel using ethanol, propylene glycol, propylene carbonate, polyethylene glycols, diisopropyl adipate, glycerol, water, etc., with appropriate gelling agents, such as Carbomers, Klucels, etc. If desired, the formulation may also contain minor amounts of non-toxic auxiliary substances such as preservatives, antioxidants, pH buffering agents, surface active agents, and the like. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art; for example, see *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, Pennsylvania, 16th Edition, 1980.

Preferably the pharmaceutical composition is administered in a single unit dosage form for continuous treatment or in a single unit dosage form ad libitum when relief of symptoms is specifically required. Representative pharmaceutical formulations containing a compound of formula I are described in Examples 4-10.

The following preparation and examples illustrate the invention but are not intended to limit its scope.

PREPARATION 1

Preparation of Compounds of Formula (3)

A. Preparation of (3) where R¹ is *tert*-Butyl and R² is Hydrogen

Methyl 4,4-dimethyl-3-oxopentanoate (15.82 g) and guanidine carbonate (20.0 g) were mixed in 80 ml of ethanol, and the solution refluxed for 16 hours. The reaction mixture was concentrated to 50 ml by removal of solvent under reduced pressure, and 20 ml of water was added. The remaining mixture was acidified to pH 5 with acetic acid, affording a white precipitate. The precipitate was collected by filtration, washed with water, and dried in a

- 49 -

vacuum oven to give 2-amino-4-hydroxy-6-tert-butylpyrimidine (12.6 g), m.p. 285-288°C (dec.).

B. Preparation of (3) where R² is Hydrogen, varying R¹

5 Similarly, replacing methyl 4,4-dimethyl-3-oxopentanoate with:

- ethyl 3-oxopentanoate;
- ethyl 4-methyl-3-oxopentanoate;
- ethyl 3-cyclobutyl-3-oxopropionate;
- 10 ethyl 3-cyclopentyl-3-oxopropionate;
- ethyl 4-methyl-3-oxohexanoate;
- ethyl 2-methyl-3-oxobutanoate;
- ethyl 3-oxo-4-phenylpentanoate;
- ethyl 3-cyclopropyl-3-oxopropionate;
- 15 ethyl 2-fluoro-3-oxobutanoate;
- ethyl 2-aminocarbonylacetate;
- ethyl 4,4,4-trifluoro-3-oxobutanoate; and
- ethyl 3-phenyl-3-oxopropionate;

(in some syntheses the methyl ester was used instead of the
20 ethyl ester; both work equally well):

and following the procedures of Preparation 1A above, the following compounds of formula (3) were prepared:

- 2-amino-6-ethyl-4-hydroxypyrimidine;
- 2-amino-4-hydroxy-6-isopropylpyrimidine, m.p. 238-
25 241°C;
- 2-amino-6-cyclobutyl-4-hydroxypyrimidine, m.p. 253-
254°C;
- 2-amino-6-cyclopentyl-4-hydroxypyrimidine, m.p. 237-
241°C (dec.);
- 30 2-amino-6-(but-2-yl)-4-hydroxypyrimidine,
m.p. 195-198°C;
- 2-amino-5,6-dimethyl-4-hydroxypyrimidine;
- 2-amino-6-benzyl-4-hydroxypyrimidine;
- 2-amino-6-cyclopropyl-4-hydroxypyrimidine;
- 35 2-amino-5-fluoro-4-hydroxy-6-methylpyrimidine;
- 2,6-diamino-4-hydroxypyrimidine;

- 50 -

2-amino-4-hydroxy-6-trifluoromethylpyrimidine; and
2-amino-4-hydroxy-6-phenylpyrimidine.

5 C. Similarly, optionally replacing methyl 4,4-dimethyl-3-oxopentanoate with other compounds of formula (1), and optionally replacing guanidine carbonate with other compounds of formula (2), and following the procedures of Preparation 1A above, other compounds of formula (3) are prepared.

10

PREPARATION 2

Preparation of Compounds of Formula (4)

15 A. Preparation of (4) where R¹ is tert-Butyl and R² is Hydrogen

2-Amino-4-hydroxy-6-tert-butylpyrimidine (8.35 g) was dissolved in 50 ml of phosphorus oxychloride and the solution refluxed for 2 hours. Excess phosphorus oxychloride was removed under vacuum and the residue dissolved in 100 ml of ethanol. The solution was adjusted to pH 8 with ice-cold concentrated ammonium hydroxide, and solvent removed under reduced pressure. The residue was filtered to give a white solid, which was recrystallized from ethanol-water to give 2-amino-4-chloro-6-tert-butylpyrimidine (3.66 g), m.p. 87.7-88.9°C.

30 B. Similarly, replacing 2-amino-4-hydroxy-6-tert-butylpyrimidine with other compounds of formula (3) and following the procedures of Preparation 2A above, the following compounds of formula (4) were prepared:

2-amino-4-chloro-6-ethylpyrimidine;
2-amino-4-chloro-6-isopropylpyrimidine, m.p. 94-97°C;
2-amino-4-chloro-6-cyclopropylmethylpyrimidine, m.p. 116.5-120.0°C;
35 2-amino-4-chloro-6-cyclobutylpyrimidine, m.p. 98-99°C;
2-amino-6-(but-2-yl)-4-chloropyrimidine, m.p. 63-65°C;

2-amino-4-chloro-6-cyclopentylpyrimidine,
m.p. 101.5-103°C.

2-amino-4-chloro-5,6-dimethylpyrimidine;

2-amino-6-benzyl-4-chloropyrimidine;

5 2-amino-4-chloro-6-cyclopropylpyrimidine;

2-amino-4-chloro-5-fluoro-6-methylpyrimidine;

2,6-diamino-4-chloropyrimidine;

2-amino-4-chloro-6-trifluoromethylpyrimidine; and

2-amino-4-chloro-6-phenylpyrimidine.

10

C. Similarly, replacing 2-amino-4-hydroxy-6-tert-butylpyrimidine with other compounds of formula (3), and following the procedures of Preparation 2A above, other compounds of formula (4) are prepared.

15

PREPARATION 3

Preparation of Compounds of Formula (9)

A. Preparation of (9) where R³ is 4,7-Difluoronaphth-1-yl
20 and R² is Hydrogen

1,6-Difluoronaphthalene (0.164 g, 1.0 mmol) was dissolved in 1,2-dichloroethane (5 ml) and cooled to 0°C. Aluminum trichloride (0.264 g, 2.0 mmol) was added as a
25 solid to the solution. Acetic anhydride (0.1 ml, 1.0 mmol) was added slowly over 20 minutes to the solution while maintaining a temperature of 0°C. The reaction was poured onto ice-cold 10% aqueous hydrochloric acid and extracted with methylene chloride (2 X 10 ml). The organic layer was
30 dried over sodium sulfate, concentrated, and purified by column chromatography to give 1-(4,7-difluoronaphth-1-yl)-ethanone as an oil (0.165 g, 80%).

B. Similarly, replacing 1,6-difluoronaphthalene with other
35 compounds of formula R³, and following the procedures of

Preparation 3 above, other compounds of formula (9) are prepared.

PREPARATION 4

5 Preparation of Compounds of Formula (15)

A. Preparation of (15) where R¹ is methyl and R² is Hydrogen

S-Methylisothiurea (22.26 g, 160 mmol) was added to a
10 solution of sodium carbonate (16.9 g, 160 mmol) in water (50 ml) and stirred at room temperature until complete dissolution of the S-methylisothiurea. Ethyl acetoacetate (10.41 g, 80 mmol) was added to the mixture in one portion. After stirring for 60 hours at room temperature, the
15 reaction was neutralized with acetic acid precipitating a white solid. The solid was collected, washed with water, and dried in vacuo to give 4-hydroxy-6-methyl-2-(methylthio)pyrimidine (9.38 g, 75%), m.p. 218-221°C.

20 B. Preparation of (15) where R² is Hydrogen, varying R¹

Similarly, replacing ethyl acetoacetate with ethyl-4-methyl-3-oxopentanoate or methyl-4,4-dimethyl-3-oxopentanoate, and following the procedures of Preparation 4A above, the following compounds of formula (15) were
25 prepared:

4-hydroxy-6-isopropyl-2-(methylthio)pyrimidine; and
6-tert-butyl-4-hydroxy-2-(methylthio)pyrimidine.

C. Preparation of (15) where R² is Hydrogen, varying R¹

30 Similarly, replacing ethyl acetoacetate with other compounds of formula (1) and following the procedures of Preparation 4A above, other compounds of formula (15) are prepared.

35

PREPARATION 5

Preparation of Compounds of Formula (16)

A. Preparation of (16) where R¹ is Methyl and R² is Hydrogen

4-Hydroxy-6-methyl-2-(methylthio)pyrimidine (9.20 g, 59 mmol) and phosphorous oxychloride (60 ml) were combined and refluxed for 3 hours. The reaction mixture was cooled to room temperature and poured onto crushed ice. The resultant aqueous mixture was extracted with ethyl acetate; and the organic layer washed with saturated aqueous sodium bicarbonate followed by a water wash, dried over magnesium sulfate, and dried in vacuo to give 4-chloro-6-methyl-2-(methylthio)pyrimidine (8.27 g, 80%), m.p. 37-38°C.

B. Similarly, replacing 4-hydroxy-6-methyl-2-(methylthio)-pyrimidine with other compounds of formula (15), and following the procedures of Preparation 5A above, the following compounds of formula (16) were prepared:

4-chloro-6-isopropyl-2-(methylthio)pyrimidine, b.p. 127-128°C @ 0.5 torr; and
6-tert-butyl-4-chloro-2-(methylthio)pyrimidine, m.p. 46-48°C.

C. Similarly, replacing 4-hydroxy-6-methyl-2-(methylthio)pyrimidine with other compounds of formula (15) and following the procedures of Preparation 5A above, other compounds of formula (16) are prepared.

PREPARATION 6

Preparation of Compounds of Formula (17)

A. Preparation of (17) where R¹ is Isopropyl, R² is Hydrogen, and R³ is 4-Fluoro-1-naphthyl

A stirred solution of 1-bromo-4-fluoronaphthalene (4.95 g) in 100 ml tetrahydrofuran was cooled to -80°C, stirred and 2.5M n-butyllithium (10 ml) was added dropwise. The mixture was stirred for 30 minutes, then trimethoxyborane (3

- 54 -

ml) added, the mixture stirred for 1 hour, then allowed to warm to room temperature, and solvent removed under reduced pressure. To this residue was added benzene (100 ml), 4-chloro-6-isopropyl-2-(methylthio)pyrimidine (4.04 g),
5 tetrakis(triphenylphosphine)palladium(0) (500. mg), and sodium carbonate (20 ml of 2M), was heated to reflux (about 80° to 90°C) for 14 hours. The mixture was filtered, and solvent was removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 2% ethyl
10 acetate/hexane, to give impure 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(methylthio)pyrimidine (4.87 g), which was used in the next reaction with no further purification.

B. Similarly, replacing 4-chloro-6-isopropyl-2-(methylthio)pyrimidine with other compounds of formula (16),
15 and following the procedures of Preparation 5A above, the following compounds of formula (17) were prepared:

4-(4-fluoronaphth-1-yl)-6-methyl-2-(methylthio)-pyrimidine, m.p. 140-142°C; and

20 4-(4-fluoronaphth-1-yl)-6-methoxy-2-(methylthio)-pyrimidine, ¹HNMR 8.19 (2H,m), 7.65 (3H,m), 7.25 (1H,dd,J=8,10 Hz), 6.45 (1H,s), 3.98 (3H,s), 2.55 (3H,s).

C. Similarly, replacing 4-chloro-6-isopropyl-2-(methylthio)pyrimidine with other compounds of formula (16)
25 and following the procedures of Preparation 6A above, other compounds of formula (17) are prepared.

D. Alternative Preparation of (17) where R¹ is Aralkyl
30 from Compounds of Formula (17) where R¹ is Alkyl

A solution of 4-(4-fluoronaphth-2-yl)-6-methyl-2-(methylthio)-pyrimidine (0.500 g, 1.76 mmol) in tetrahydrofuran (2 ml) was added dropwise to a solution of lithium diisopropylamide (1.2 eq) in tetrahydrofuran (10 ml)
35 cooled to -70°C. After stirring for 30 minutes, benzyl bromide (0.251 ml, 2.11 mmol) was added to the solution in

- 55 -

one portion. The solution was warmed to room temperature and diuted with ethyl acetate (50 ml), poured into water (50 ml). The organic layer was separated, dried over magnesium sulfate and concentrated in vacuo, and the resultant oil
5 purified by column chromatography to give 4-(4-fluoronaphth-1-yl)-2-methylthio-6-phenethylpyrimidine (0.342 g, 52%).

E. Similarly, replacing 4-(4-fluoronaphth-2-yl)-6-methyl-2-(methylthio)pyrimidine with other compounds of formula
10 (16) where R^1 is alkyl and following the procedures of Preparation 6D above, the following compounds of formula (17) were prepared:

4-(4-fluoronaphth-1-yl)-6-(2-hydroxyphenethyl)-2-(methylthio)pyrimidine; and
15 4-(4-fluoronaphth-1-yl)-6-(3-hydroxypropyl)-2-(methylthio)pyrimidine.

F. Similarly, replacing 4-(4-fluoronaphth-2-yl)-6-methyl-2-(methylthio)pyrimidine with other compounds of formula
20 (16) and following the procedures of Preparation 6C above, where R^1 is lower alkyl, other compounds of formula (17) are prepared.

PREPARATION 7Preparation of Compounds of Formula (18)

- A. Preparation of (18) where R¹ is Isopropyl, R² is
5 Hydrogen, and R³ is 4-Fluoro-1-naphthyl
4-(4-Fluoronaphth-1-yl)-2-methylthio-6-phenethyl-
pyrimidine (0.342 g, 0.914 mmol) was dissolved in methylene
chloride at room temperature. meta-Chloroperoxybenzoic acid
(55-60%, 0.554 g, 1.83 mmol) was added in small portions.
10 After 16 hours, the reaction mixture was washed with
saturated aqueous sodium bisulfite. The organic layer was
washed with saturated aqueous sodium bicarbonate and water,
dried over magnesium sulfate, and concentrated in vacuo to
give 4-(4-fluoronaphth-1-yl)-2-methylsulfonyl-
15 6-phenethylpyrimidine (0.402 g, 97%) as an oil, ¹HNMR 8.07
(1H,m), 7.85 (1H,m), 7.47 (2H,m), 7.32 (1H,s), 7.13 (7H,m),
3.29 (2H,m), 3.07 (2H,m).
- B. Similarly, replacing 4-(4-fluoronaphth-1-yl)-2-
20 methylthio-6-phenethylpyrimidine with other compounds of
formula (17), and following the procedure of Preparation 7A
above, the following compounds of formula (18) were
prepared.
- 4-(4-fluoronaphth-1-yl)-6-(2-hydroxyphenethyl)-
25 2-methylsulfonyl-pyrimidine, m.p. 88.1-90.0°C;
4-(4-fluoronaphth-1-yl)-6-(3-hydroxypropyl)-
2-methylsulfonyl-pyrimidine, ¹HNMR 8.21 (2H,m), 7.69
(1H,dd,J=5.3,8.2 Hz), 7.68 (1H,s), 7.61 (2H,m), 7.24
(1H,dd,J=8,10 Hz), 3.76 (2H,t,J=7.5 Hz), 3.40 (3H,s), 3.09
30 (2H,t,J=7.5 Hz), 2.11 (2H,m);
4-(4-fluoronaphth-1-yl)-6-methoxy-2-methylsulfonyl-
pyrimidine, ¹HNMR 8.20 (2H,m), 7.64 (3H,m), 7.25
(1H,dd,J=8,10 Hz), 7.15 (1H,s), 4.20 (3H,s), 3.39 (3H,s);
and
35 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonyl-
pyrimidine, m.p. 96.1-97.1°C.

- C. Similarly, replacing 4-(4-fluoronaphth-1-yl)-2-methylthio-6-phenethylpyrimidine with other compounds of formula (17), and following the procedure of Preparation 7A above, other compounds of formula (18) are prepared.

EXAMPLE 1

Preparation of a Compound of Formula I

- 10 A. Preparation of I where R¹ and R² are Methyl, R³ is Naphth-1-yl, and R⁴ and R⁵ are Hydrogen

A stirred heterogeneous solution of 1-naphthyl boronic acid (0.382 g), 2-amino-4-chloro-5,6-dimethylpyrimidine (0.350 g), tetrakis(triphenylphosphine)palladium(0) (0.153 g), ethyl alcohol (8 ml), water (4 ml), 1,2-dimethoxyethane (8 ml) and sodium carbonate (0.85 g), was heated to reflux (about 80° to 90°C) for 14 hours. The solution was then cooled to room temperature, filtered and extracted with ethyl acetate. The solvent was removed under reduced pressure and the resultant yellow solid was recrystallized to give 2-amino-5,6-dimethyl-4-(naphth-1-yl)-pyrimidine (0.213 g), m.p. 213.5-215.1°C.

- 25 B. Similarly, optionally replacing 2-amino-4-chloro-5,6-dimethylpyrimidine with other compounds of formula (4), and optionally replacing 1-naphthyl boronic acid with other compounds of formula (5), and following the procedures of Example 1A above, the following compounds of formula I were prepared:

- 30 2-amino-6-cyclopentyl-4-(naphth-1-yl)-pyrimidine,
m.p. 146.8-147.4°C;
2-amino-6-(but-2-yl)-4-(naphth-1-yl)-pyrimidine,
m.p. 109.6-110.8°C;
2-amino-6-(2-methylpropyl)-4-(naphth-1-yl)-pyrimidine
35 hydrobromide, m.p. 147.0-151.5°C;

- 2-amino-6-(tert-butyl)-4-(naphth-1-yl)-pyrimidine,
m.p. 161.0-161.3°C;
- 2-amino-6-benzyl-4-(naphth-1-yl)-pyrimidine,
m.p. 147.9-148.2°C;
- 5 2-amino-6-cyclobutyl-4-(naphth-1-yl)-pyrimidine,
m.p. 147-148°C;
- 2-amino-6-cyclopropyl-4-(naphth-1-yl)-pyrimidine,
m.p. 182.8-184.0°C;
- 2-amino-4-(naphth-1-yl)-6-n-propylpyrimidine,
10 m.p. 119.5-120.5°C;
- 2-amino-6-isopropyl-4-(naphth-1-yl)-pyrimidine,
m.p. 124-126°C;
- 2-amino-5-fluoro-6-methyl-4-(naphth-1-yl)-pyrimidine,
m.p. 155-157°C;
- 15 2-amino-6-ethyl-4-(naphth-1-yl)-pyrimidine
hydrochloride, m.p. 157-160°C;
- 2,6-diamino-4-(naphth-1-yl)-pyrimidine hydrochloride,
m.p. >290°C;
- 2-amino-6-trifluoromethyl-4-(naphth-1-yl)-pyrimidine,
20 m.p. 152-154°C;
- 2-amino-4-(naphth-1-yl)-6-phenylpyrimidine
hydrochloride, m.p. 232-236°C;
- 2-amino-4-(3-fluorophenyl)-6-methylpyrimidine,
m.p. 140.6-141.4°C;
- 25 2-amino-4-(5-chlorothiophen-2-yl)-6-methylpyrimidine,
m.p. 186.1-187.3°C;
- 2-amino-4-(3-methoxyphenyl)-6-methylpyrimidine,
m.p. 125.8-129.6°C;
- 2-amino-6-methyl-4-(3-nitrophenyl)-pyrimidine,
30 m.p. 198.5-199.6°C;
- 2-amino-4-(3-chloro-4-fluorophenyl)-6-methylpyrimidine,
m.p. 163.8-165.5°C;
- 2-amino-4-(3,5-dichlorophenyl)-6-methylpyrimidine,
m.p. 187.0-187.9°C;
- 35 2-amino-6-methyl-4-(3-trifluoromethylphenyl)-
pyrimidine, m.p. 122.0-122.8°C;

- 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine
hydrochloride, m.p. 226°C;
- 2-amino-4-(4-fluoronaphth-1-yl)-6-(3,3,3-
trifluoropropyl)-pyrimidine hydrochloride, m.p. 152-155°C;
- 5 2-amino-4-(5-fluoronaphth-1-yl)-6-isopropylpyrimidine,
m.p. 86-88°C;
- 2-amino-4-(2-fluoronaphth-1-yl)-6-isopropylpyrimidine
hydrochloride, m.p. 205-206°C;
- 2-amino-4-(2-fluoronaphth-1-yl)-6-methoxypyrimidine
10 hydrochloride, m.p. 189-190°C;
- 2-amino-4-(4-fluoronaphth-1-yl)-6-methoxypyrimidine
hydrochloride, m.p. >280°C;
- 2-amino-4-(4-fluoronaphth-1-yl)-6-(2,2,2-
trifluoroethoxy)-pyrimidine hydrochloride, m.p. 206.1-208°C;
- 15 2-amino-6-tert-butyl-4-(2-fluoronaphth-1-yl)-pyrimidine
hydrochloride, m.p. 230-233°C;
- 2-amino-4-(2-fluoronaphth-1-yl)-6-methylpyrimidine,
m.p. 149-150°C;
- 2-amino-4-(2-methylnaphth-1-yl)-6-isopropylpyrimidine
20 hydrochloride, m.p. 193-194°C;
- 2-amino-4-(6-methylacenaphthen-5-yl)-6-methyl-
pyrimidine, m.p. 198-199°C;
- 2-amino-6-cyclopropyl-4-(1H-indol-4-yl)-pyrimidine
hydrochloride, m.p. >280°C;
- 25 2-amino-6-tert-butyl-4-(1H-indol-4-yl)-pyrimidine,
m.p. 171-173°C;
- 2-amino-4-(8-hydroxymethylnaphth-1-yl)-6-methyl-
pyrimidine, m.p. 206-208°C;
- 2-amino-4-(1H-indol-7-yl)-6-isopropylpyrimidine,
30 m.p. 143-145°C;
- 2-amino-4-(4-amino-5-chloro-2-methoxyphenyl)-6-
isopropylpyrimidine hydrochloride, m.p. 187.1-190.6°C;
- 2-amino-6-cyclobutyl-4-(1H-indol-4-yl)-pyrimidine,
m.p. 225-226°C;
- 35 2-amino-6-(3-methylbutyl)-4-(naphth-1-yl)-pyrimidine
hydrochloride, m.p. 151.5-153°C; and

- 60 -

2-amino-4-(4-amino-5-chloro-2-methoxyphenyl)-6-methylpyrimidine, m.p. 183-184°C.

- C. Similarly, optionally replacing 2-amino-4-chloro-5,6-dimethylpyrimidine with other compounds of formula (4), and optionally replacing 1-naphthyl boronic acid with other compounds of formula (5), and following the procedures of Example 1A above, other compounds of formula I are prepared.

10

EXAMPLE 2Alternative Preparation of a Compound of Formula I

- A. Preparation of I where R¹ is n-Propyl, R² is Hydrogen, R³ is 4-Fluoronaphth-1-yl, and R⁴ and R⁵ are Hydrogen
- 15 To a stirred solution of 1-bromo-4-fluoronaphthalene (0.5 g) in 10 ml of tetrahydrofuran at -78°C under nitrogen was added n-butyllithium (1.6M, 1.53 ml) dropwise. The solution was allowed to stir for 5 minutes, then trimethoxyborane (0.33 ml) was added dropwise. The solution was
- 20 allowed to warm to room temperature and the solvent removed under reduced pressure to give a solid, dimethoxy-(4-fluoronaphth-1-yl)borane, a compound of formula (7).

- The solid was dissolved in 5 ml of benzene, and 2-amino-4-chloro-6-n-propylpyrimidine (0.381 g), tetrakis-(triphenylphosphine)palladium(0) (0.100 g) and 6 ml of 2M aqueous sodium carbonate were added. The heterogeneous solution was heated to reflux (about 80° to 90°C) for 1 hour, then the solution cooled to room temperature, diluted
- 30 with ethyl acetate and filtered. The filtrate was concentrated in vacuo and the residue chromatographed on silica gel, eluting with a mixture of hexanes/ethyl acetate, to give 2-amino-4-(4-fluoronaphth-1-yl)-6-n-propylpyrimidine (0.110 g), m.p. 136.9-137.4°C.

35

- 61 -

B. Similarly, optionally replacing 1-bromo-4-fluoro-naphthalene with other compounds of formula (6), and optionally replacing 2-amino-4-chloro-6-n-propylpyrimidine with other compounds of formula (4), and following the
5 procedures of Example 2A above, the following compounds of formula I were prepared:

- 2-amino-4-(4-chloronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine hydrochloride, m.p. 198.2-199.8°C;
- 2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)-
10 pyrimidine hydrochloride, m.p. 191.3-193.0°C;
- 2-amino-4-(4-chloronaphth-1-yl)-6-ethylpyrimidine, m.p. 142.7-143.2°C;
- 2-amino-4-(4-methylnaphth-1-yl)-6-isopropylpyrimidine, m.p. 143.9-145.0°C;
- 15 2-amino-6-(tert-butyl)-4-(4-fluoronaphth-1-yl)-pyrimidine hydrochloride, m.p. 193-194°C;
- 2-amino-4-(4,5-dimethylnaphth-1-yl)-6-methylpyrimidine, m.p. 194-195°C;
- 2-amino-4-(4,5-difluoronaphth-1-yl)-6-isopropyl-
20 pyrimidine, m.p. 123-124°C;
- 2-amino-4-(4-chloronaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 183.2-185.6°C;
- 2-amino-6-cyclopropyl-4-(4-fluoronaphth-1-yl)-pyrimidine, m.p. 150.7-151.5°C;
- 25 2-amino-6-cyclopropylmethyl-4-(4-fluoronaphth-1-yl)-pyrimidine hydrochloride, m.p. 128.4-129.4°C;
- 2-amino-6-cyclobutyl-4-(4-fluoronaphth-1-yl)-pyrimidine hydrochloride, m.p. 168-171°C;
- 2-amino-4-(4,5-difluoronaphth-1-yl)-6-methylpyrimidine,
30 m.p. 200°C;
- 2-amino-4-(1H,3H-benzo[de]isochromen-6-yl)-6-methylpyrimidine, m.p. 216-218°C;
- 2-amino-4-(acenaphth-5-yl)-6-isopropylpyrimidine, m.p. 167-168°C;
- 35 2-amino-6-methyl-4-(phenanthren-9-yl)-pyrimidine, m.p. 191.3-191.8°C;

- 62 -

- 2-amino-4-(4-methylnaphth-1-yl)-6-methylpyrimidine,
m.p. 175.2-176.6°C;
- 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine
hydrochloride, m.p. 156-158°C;
- 5 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine
maleate, m.p. 155-157°C;
- 2-amino-6-ethyl-4-(2-methyl-4-fluoronaphth-1-yl)-
pyrimidine, m.p. 121-122°C;
- 2-amino-4-(acenaphth-5-yl)-6-methylpyrimidine,
10 m.p. 211-213°C;
- 2-amino-4-(isoquinolin-4-yl)-6-methylpyrimidine,
m.p. 212.0-213.5°C;
- 2-amino-4-(quinolin-8-yl)-6-methylpyrimidine,
m.p. 194.8-195.5°C;
- 15 2-amino-4-(4-fluoronaphth-1-yl)-pyrimidine,
m.p. 203.4-204.1°C;
- 2-amino-6-ethyl-4-(4-fluoronaphth-1-yl)-pyrimidine
hydrochloride, m.p. 198-199°C;
- 2-amino-4-(4-fluoronaphth-1-yl)-6-methylpyrimidine
20 hydrochloride, m.p. 238.3-238.6°C; and
- 2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine
hydrochloride, m.p. 216.6-219.4°C.
- C. Similarly, optionally replacing 1-bromo-4-
25 fluoronaphthalene with other compounds of formula (6), and
optionally replacing 2-amino-4-chloro-6-n-propylpyrimidine
with other compounds of formula (4), and following the
procedures of Example 2A above, other compounds of formula I
are prepared.

EXAMPLE 3Alternative Preparation of a Compound of Formula I

- A. Preparation of I where R¹ is Methyl, R² is Hydrogen, R³
5 is 6-Methoxy-3,4-Dihydro-2H-Quinolin-1-yl, and R⁴ and
10 R⁵ are Hydrogen

A flask containing 6-methoxy-1,2,3,4-tetrahydro-quinoline (1.33 g), 2-amino-4-chloro-6-methylpyrimidine (1.00 g), sulfuric acid (0.6 g), and 100 ml of water was
10 heated on a steam bath for 2 hours. The solution was then cooled to room temperature and treated with ammonium hydroxide until the solution was basic (pH 8-9). The resultant solid, which precipitated from solution, was collected by filtration and recrystallized from ethyl
15 alcohol to give 2-amino-4-(6-methoxy-3,4,-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine (0.93 g), m.p. 175.2-175.9°C.

- B. Similarly, optionally replacing 6-methoxy-1,2,3,4-
20 tetrahydroquinoline with other compounds of formula (8), and optionally replacing 2-amino-4-chloro-6-methylpyrimidine with other compounds of formula (4), and following the procedures of Example 3A above, the following compounds of formula I were prepared:

25 2-amino-4-(6-fluoro-3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine, m.p. 156-157°C;

2-amino-6-chloro-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine hydrochloride, m.p. >180°C (dec);

2-amino-4-(indol-1-yl)-6-methylpyrimidine
30 hydrochloride, m.p. 256-260°C;

2,6-diamino-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine dihydrochloride, m.p. 196-197°C;

6-(3,4-dihydro-2H-quinolin-1-yl)-9H-purin-2-ylamine, m.p. 203.5-204.0°C;

35 2-amino-4-(2-methyl-3,4-dihydro-2H-quinolin-1-yl)-6-methylpyrimidine, m.p. 141-144°C;

- 64 -

- 2-amino-4-(6-methoxy-3,4-dihydro-2H-quinolin-1-yl)-
6-trifluoromethylpyrimidine, m.p. 175.6-177.5°C;
2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-
6-ethylpyrimidine, m.p. 141.4-142.1°C;
5 2-amino-6-methyl-4-(6-methyl-3,4-dihydro-2H-quinolin-1-
yl)-pyrimidine, m.p. 170.6-171.4°C;
2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-
6-trifluoromethylpyrimidine, m.p. 162-164°C;
2-amino-4-(6-fluoro-2-methyl-3,4-dihydro-2H-quinolin-1-
10 yl)-6-methylpyrimidine, m.p. 154.9-155.6°C;
4-(3,4-dihydro-2H-quinolin-1-yl)-2-(methylamino)-
pyrimidine ;
[2-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidin-4-
yl)methylamine;
15 2-amino-6-methyl-4-(2,3,4,5-tetrahydro-benzo[b]azepin-
1-yl)-pyrimidine, m.p. 182.6-184.2°C;
2-amino-4-(7,8-dihydro-6H-5-oxa-9-benzocyclohepten-9-
yl)-6-methylpyrimidine, m.p. 189.9-192.0°C;
2-amino-4-(2,3-dihydro-benzo[1,4]oxazin-4-yl)-
20 6-methylpyrimidine, m.p. 177.7-178.5°C;
2-amino-4-(2,3-dihydro-indol-1-yl)-6-methylpyrimidine,
m.p. 247.7-248.0°C;
2-amino-4-(2-methyl-2,3-dihydro-indol-1-yl)-
6-methylpyrimidine, m.p. 182.9-183.4°C;
25 2-amino-4-(3,4-dihydro-2H-quinolin-1-yl)-
6-methylpyrimidine hydrochloride, m.p. 261.5-262.3°C; and
2-amino-4-(3,4-dihydro-1H-isoquinolin-2-yl)-
6-methylpyrimidine, m.p. 142.2-143.3°C.

- 30 C. Preparation of I where R¹ is Chloro, R² is Hydrogen,
R³ is 3,4-Dihydro-2H-Quinolin-1-yl, and R⁴ and R⁵ are
Hydrogen

1,2,3,4,-tetrahydroquinoline (2.66 g, 20 mmol) and
2-amino-4,6-dichloropyrimidine (3.30 g, 20 mmol) were
35 dissolved in 10 ml of N,N-dimethylformamide (DMF), and the
entire solution was heated to 70-90°C for 24 hours. DMF was

- 65 -

removed under vacuum, and the residue was refluxed with ethyl acetate to give 4.0 g of a solid; the solid was chromatographed on silica gel, eluting with methylene chloride, to give 2-amino-6-chloro-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine (400 mg), m.p. 167.1-167.5°C; 2-amino-6-chloro-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine hydrochloride, m.p. 179°C (dec.).

D. Similarly, optionally replacing 6-methoxy-1,2,3,4-tetrahydroquinoline with other compounds of formula (8), and optionally replacing 2-amino-4-chloro-6-methylpyrimidine with other compounds of formula (4), and following the procedures of Example 3A or 3C above, other compounds of formula I are prepared.

EXAMPLE 4

Alternative Preparation of a Compound of Formula I

A. Preparation of I where R¹ is N,N-diethylamino, R² is Hydrogen, R³ is 3,4-Dihydro-2H-Quinolin-1-yl, and R⁴ and R⁵ are Hydrogen

Excess diethylamine was added to a solution of 2-amino-6-chloro-4-(1,2,3,4-tetrahydroquinolin-1-yl)-pyrimidine (250 mg) in 5 ml of ethylene glycol. The mixture was heated for 2 days at 100°C. The crude product was purified by chromatography to give 300 mg of a solid. Treatment of the solid with hydrochloric acid-ethanol alcohol yielded 2-amino-6-diethylamino-4-(3,4-dihydro-2H-quinolin-1-yl)-pyrimidine hydrochloride, m.p. 167-170°C.

B. Similarly, optionally replacing diethylamine with other amines of formula HNR⁶R⁷, and optionally replacing 2-amino-6-chloro-4-(1,2,3,4-tetrahydroquinolin-1-yl)-pyrimidine with other compounds of formula I where R¹ is chloro, and

- 66 -

following the procedures of Example 4A above, other compounds of formula I where R^1 is $-NR^6R^7$ are prepared.

EXAMPLE 5

5 Alternative Preparation of a Compound of Formula I

A. Preparation of I where R^1 is Methyl, R^2 is Hydrogen,
 R^3 is 1H-Indol-4-yl, and R^4 and R^5 are Hydrogen

 4-Acetylmindole (0.101 g) was refluxed in 5 ml of ethyl
10 acetate. Sodium hydride (0.20 g, 60% oil dispersion) was
added in portions to the refluxing solution until thin layer
chromatography analysis showed complete consumption of the
starting material. The reaction mixture was quenched with
water and acidified to pH 3. The ethyl acetate layer was
15 dried (magnesium sulfate) and concentrated to give a crude
product. The crude material was chromatographed on silica
gel, eluting with a 4:1 mixture of hexane/ethyl acetate to
give 1-(1H-indol-4-yl)-1,3-butanedione (0.104 g), a compound
of formula (11), m.p. 104-105°C.

20

B. 1-(1H-Indol-4-yl)-1,3-butanedione (0.096 g) was mixed
with guanidine carbonate (0.070 g), and the mixture was
heated to 150°C for 3 hours. Additional guanidine carbonate
(0.070 g) was added, and the mixture continued to heat for
25 another 2 hours. The reaction mixture was warmed with ethyl
acetate, filtered, and the ethyl acetate layer was
concentrated to give a solid (0.090 g). Flash
chromatography on silica gel and eluting with a 1:1 mixture
of hexane/ethyl acetate, yielded 2-amino-4-(1H-indol-4-yl)-
30 6-methylpyrimidine (0.029 g), m.p. 242 -243.5°C.

C. Similarly, replacing 4-acetylmindole with 1-
acetylnaphthalene in step 5A above, and replacing guanidine
carbonate with 1-arginine in step B, and following the
35 procedures of Example 5A and 5B, the compound 2-amino-5-(6-

- 67 -

methyl-4-naphth-1-yl)-pyrimidin-2-ylamino)-pentanoic acid, m.p. 264-266°C was prepared.

D. Similarly, replacing 4-acetylindole with ethyl(1-naphthoyl)acetate in step 5A, and following the procedures of Example 5A and 5B, the compound 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 270-272°C was prepared.

10 E. Similarly, replacing 1-(1H-indol-4-yl)-1,3-butanedione with 1-(3-chlorophenyl)-1,3-butanedione and following the procedures of Example 5B above, the compound 2-amino-4-(3-chlorophenyl)-6-methylpyrimidine, m.p. 131.6-132.3°C was prepared.

15

F. Preparation of I where R¹ is Methyl, R² is Hydrogen, R³ is 2,3-dihydro-1,4-benzodioxin-5-yl, and R⁴ and R⁵ are Hydrogen

1-(2,3-Dihydro-1,4-benzodioxin-5-yl)-ethanone (1.2 g) was dissolved in 20 ml of ethyl acetate, and sodium hydride (0.33 g, 60% oil dispersion) was added. The reaction mixture was heated to 80°C overnight, quenched with water, and neutralized with carbon dioxide to give an oily product of 1-(2,3-dihydro-1,4-benzodioxin-5-yl)butan-1,3-dione (0.37 g).

25

The 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-butan-1,3-dione (0.37 g), was mixed with guanidine carbonate (0.22 g), and the mixture was heated to 135°C for 1 hour. The dark product was taken up in methylene chloride, filtered, and concentrated. The residue was chromatographed on silica gel, eluting with a 3:2 mixture of ethyl acetate/hexane, to give a solid (0.16 g), which was treated with hydrochloric acid-ethanol to give 2-amino-4-(2,3-dihydro-1,4-benzodioxin-5-yl)-6-methylpyrimidine hydrochloride (0.125 g), m.p. 240-242°C.

35

- 68 -

G. Preparation of I where R¹ and R² are Hydrogen,
R³ is 1-methylindol-3-yl, and R⁴ and R⁵ are Hydrogen

3-Acetyl-1-methylindole (0.870 g) was dissolved in 3 ml
5 of absolute ethanol. Tert-butoxybis(dimethylamino)methane
(Bredereck's reagent) (0.960 g) in 3 ml of ethanol was added
to this solution at reflux temperature. The solution was
refluxed for 2 days and the solvent was removed at room
temperature under vacuum. The residue was triturated with a
10 7:3 mixture of hexane/ethyl acetate to give a solid (0.094
g).

The solid was mixed with guanidine carbonate (0.037 g)
and the mixture was heated to 120°C for 14 hours. The
15 reaction mixture was dissolved in hot absolute ethyl
alcohol, filtered, and recrystallized to give a white,
crystalline solid of 2-amino-4-(1-methylindol-3-yl)-
pyrimidine (0.039 g). Treatment of the crystalline solid
with hydrochloric acid-ethyl alcohol and recrystallization
20 of the salt from ethanol gave 2-amino-4-(1-methylindol-3-
yl)-pyrimidine hydrochloride (0.0098 g), m.p. 274-276°C.

H. Preparation of I where R¹ is Isopropyl, R² is Hydrogen,
R³ is 4,7-difluoronaphth-1-yl, and R⁴ and R⁵ are

25 Hydrogen

1-(4,7-difluoronaphth-1-yl)-ethanone (0.150 g, 0.72
mmol) was dissolved in dry dioxane (1 ml) and cooled to 0°C.
Sodium hydride (0.145 g, 3.6 mmol, 60 wt.% dispersion) was
added and the reaction mixture was stirred for 1 hour at
30 room temperature. Ethyl isobutyrate (1.0 ml, 7.2 mmol) was
added in one portion and the solution was heated to reflux
for 15 minutes. After cooling to room temperature, the
reaction mixture was poured onto 10% aqueous hydrochloric
acid and extracted with methylene chloride. The organic
35 layer was dried over sodium sulfate and purified by column

- 69 -

chromatography to give 1-(4,7-difluoronaphth-1-yl)-4-methylpentane-1,3-dione (0.120 g, 72%).

I. 1-(4,7-difluoronaphth-1-yl)-4-methylpentane-1,3-dione
5 (0.114 g, 0.5 mmol) was combined with guanidine carbonate (0.180 g, 0.5 mmol) and heated to 150°C for 6 hours. The reaction was cooled to room temperature and directly purified by column chromatography to give 2-amino-4-(4,7-difluoronaphth-1-yl)-6-isopropylpyrimidine (0.052 g, 34%),
10 m.p. 103-105°C.

J. Similarly, replacing 1-(4,7-difluoronaphth-1-yl)-ethanone with 1-(4,6-difluoronaphth-1-yl)-ethanone, 1-(4,8-difluoronaphth-1-yl)-ethanone, 1-(4-methoxynaphth-1-yl)-ethanone, or 1-(1-methyl-1H-indol-4-yl)-ethanone in step 5H,
15 and optionally replacing ethyl isobutyrate with 4,4-dimethyl-3-oxopentanoate or 4,4-dimethyl-3-oxopentanoate, or ethyl-2-fluoroisobutyrate, and guanidine with substituted guanidine salts in step 5I, and following
20 the procedures of Example 5H and 5I, the following compounds were prepared:

2-amino-4-(4,6-difluoronaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 136-138°C;

2-amino-4-(4,8-difluoronaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 216-219°C;
25

2-amino-4-(4-methoxynaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 196-197°C;

2-amino-6-tert-butyl-4-(4-methoxynaphth-1-yl)-pyrimidine hydrochloride, m.p. 219-220.5°C;

2-amino-4-(1H-indol-4-yl)-6-isopropylpyrimidine hydrochloride, m.p. 211-212°C;
30

2-amino-4-(1-methyl-1H-indol-4-yl)-6-isopropylpyrimidine, m.p. 128-130°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine, m.p. 135.5-137.0°C;
35

- 70 -

2-amino-4-(4-fluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine hydrochloride, m.p. 186.6-187.8°C;

4-(4-fluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-2-methylaminopyrimidine, m.p. 149-151°C;

5 2-amino-4-(4-methoxynaphth-1-yl)-6-methylpyrimidine hydrochloride, m.p. 247.0-249.5°C;

2-amino-6-ethyl-4-(4-methoxynaphth-1-yl)-pyrimidine hydrochloride, m.p. 218.5-218.9°C; and

2-amino-4-(4,6-difluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine hydrochloride, m.p. 129.6-131.3°C.

EXAMPLE 6

Alternative Preparation of a Compound of Formula I

15 A. Preparation of I where R¹ is Chloro, R² is Hydrogen, R³ is Naphth-1-yl, and R⁴ and R⁵ are Hydrogen

2-Amino-6-hydroxy-4-(naphth-1-yl)-pyrimidine (900 mg) was added to a solution of chlorosulfonic acid (0.05 ml) in 2.5 ml of phosphorus oxychloride, and the mixture was
20 stirred at 95°C for 6 hours. The mixture was poured onto ice, neutralized with potassium carbonate, and extracted with ethyl acetate. The crude product (70 mg) was purified by silica gel chromatography, eluting with methylene chloride, and treated with hydrochloric acid-ethanol to give
25 2-amino-6-chloro-4-(naphth-1-yl)-pyrimidine hydrochloride (25 mg), m.p. 248-250°C.

B. Preparation of I where R¹ and R² are Hydrogen, R³ is Naphth-1-yl, and R⁴ and R⁵ are Hydrogen

30 2-Amino-6-chloro-4-(naphth-1-yl)-pyrimidine (170 mg) was dissolved in 10 ml of methyl alcohol at 0°C. 10% Palladium on activated carbon (70 mg) and approximately 1 ml of 20% sodium hydroxide were added to the solution, and the mixture was hydrogenated (1 atmosphere) for 1 hour to give
35 solid 2-amino-4-(naphth-1-yl)-pyrimidine (80 mg). Treatment of the solid with hydrochloric acid-ethyl alcohol yielded

- 71 -

2-amino-4-(naphth-1-yl)-pyrimidine hydrochloride (25 mg),
m.p. 181-184°C.

EXAMPLE 75 Alternative Preparation of a Compound of Formula I

A. Preparation of I where R¹ is Methoxy, R² is Hydrogen,
 R³ is Naphth-1-yl, and R⁴ and R⁵ are Hydrogen

1-Acetonaphthalene (33 g) in carbon disulfide (15 g)
10 was added over 15 minutes to a 12°C solution containing 195
ml of 1M potassium tert-butoxide in 400 ml of ether. The
reaction mixture was allowed to warm to room temperature,
re-cooled to 10-12°C, and then methyl iodide (55.0 g) was
added dropwise over 45 minutes. The reaction mixture was
15 brought to room temperature for 16 hours, filtered, and
concentrated. The residue was recrystallized from 125 ml of
methyl alcohol to give 3,3-(bis-methylsulfanyl)-(1-naphth-1-
yl)-prop-2-en-1-one (20.1 g), m.p. 73-79°C.

20 B. The 3,3-(bis-methylsulfanyl)-(1-naphthalen-1-yl)prop-2-
en-1-one (1.28 g) was added to 10 ml of a methanolic
solution of sodium hydride (640 mg, 60% oil dispersion) and
guanidine carbonate (630 g). The reaction mixture was
refluxed for 6 hours, poured into ethyl acetate, and washed
25 with saturated sodium bicarbonate, water, and brine. The
organic layer was dried over potassium carbonate and
concentrated to about 5 ml to give a crystalline solid of
2-amino-6-methoxy-4-(naphth-1-yl)-pyrimidine,
m.p. 159.6-159.8°C. Treatment of the crystalline solid with
30 hydrochloric acid-ethyl alcohol gave 2-amino-4-methoxy-6-
(naphth-1-yl)-pyrimidine hydrochloride (300 mg), m.p. 184-
185°C.

C. Similarly, replacing the methanolic solution with the
35 corresponding alcohol (ethylene glycol, isopropyl alcohol,

- 72 -

ethyl alcohol) and following the procedures of Example 7B above, the following compounds of formula I were prepared:

2-amino-6-(2-hydroxyethoxy)-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 199-201°C;

5 2-amino-6-isopropoxy-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 165-167°C; and

2-amino-6-ethoxy-4-(naphth-1-yl)-pyrimidine hydrochloride, m.p. 194-195°C.

10 D. Preparation of I where R¹ is Methylthio, R² is Hydrogen.

R³ is Naphth-1-yl, and R⁴ and R⁵ are Hydrogen

The 3,3-(bis-methylsulfanyl)-(1-naphth-1-yl)-prop-2-en-1-one (1.13 g) was added to a mixture of sodium hydride
15 (0.38 g, 60% oil dispersion) and guanidine carbonate (0.40 g) in 10 ml of N,N-dimethylformamide (DMF) at room temperature. After 1 hour, the mixture was heated to 150°C for 5 hours. Extractive work-up gave a crude product which was chromatographed on silica gel, eluting with a 6:1
20 mixture of hexane/ethyl acetate to give 2-amino-4-methylthio-6-(1-naphthyl)-pyrimidine (140 mg). Treatment of the free base with hydrochloric acid-ethyl alcohol gave 2-amino-6-methylthio-4-(naphth-1-yl)-pyrimidine hydrochloride (80 mg), m.p. 255-259°C (dec.).

25

EXAMPLE 8

Alternative Preparation of a Compound of Formula I

A. Preparation of I where R¹ is Isopropyl, R² is Hydrogen,
30 R³ is Naphth-1-yl, R⁴ is Ethyl and R⁵ is Hydrogen

4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonylpyrimidine (0.100 g, 0.29 mmol) was added to a solution of ethylamine (0.33 ml, 5.8 mmol) in ethanol (1 ml). The reaction vessel was placed in a sonication bath
35 for 6 hours at a bath temperature of 45°C. The ethanol was removed in vacuo leaving a viscous oil. The oil was

- 73 -

crystallized from ethanol and water to give 2-ethylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (49%), m.p. 77-78°C.

- 5 B. Similarly, replacing ethylamine with other amines of formula NHR^4R^5 and optionally replacing 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonylpyrimidine with other compounds of formula (18), and following the procedures of Example 8A above, the following compounds of formula I were
10 prepared:

- 4-(4-fluoronaphth-1-yl)-2-hydrazino-6-isopropylpyrimidine hydrochloride, m.p. 141-145°C;
4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(piperazin-1-yl)-pyrimidine fumarate, m.p. 196.1-196.6°C;
15 2-(2-methoxyethylamino)-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 87.1-87.7°C;
4-(4-fluoronaphth-1-yl)-6-isopropyl-2-n-propylamino-pyrimidine, m.p. 99.6-99.9°C;
2-allylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-
20 pyrimidine, m.p. 92.8-93.4°C;
4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(piperidin-1-yl)-pyrimidine, m.p. 70-72°C;
2-benzylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 73-74°C;
25 2-cyclopropylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 100.1-100.8°C;
2-(2-hydroxyethylamino)-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine hydrochloride, m.p. 70-71°C;
4-(4-fluoronaphth-1-yl)-6-isopropyl-2-morpholino-
30 pyrimidine, m.p. 81-83°C;
2-butylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 87-88°C;
2-butylamino-4-(4-fluoronaphth-1-yl)-6-methylpyrimidine hydrochloride, m.p. 137-139°C;
35 2-dimethylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 41-42°C;

- 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylamino-pyrimidine, m.p. 115-116°C;
- 4-(4-fluoronaphth-1-yl)-6-(2-hydroxy-2-phenethyl)-2-methylaminopyrimidine, m.p. 138.1-139.2°C;
- 5 4-(4-fluoronaphth-1-yl)-6-phenethyl-2-methylamino-pyrimidine hydrochloride, m.p. 130.7-131.2°C;
- 4-(4-fluoronaphth-1-yl)-2-isopropylamino-6-methoxypyrimidine hydrochloride, m.p. 191.3-191.6°C;
- 2-(dimethylamino)ethylamino-4-(4-fluoronaphth-1-yl)-
- 10 6-isopropylpyrimidine hydrochloride, m.p. 176.5°C;
- 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(methylamino)-ethylamino-pyrimidine hydrochloride, m.p. 152-153°C;
- 4-(4-fluoronaphth-1-yl)-6-(2-hydroxypropyl)-2-(methylamino)-ethylamino-pyrimidine hydrochloride, m.p. 125-
- 15 130°C;
- 2-(2-hydroxyethyl)amino-4-(4-fluoronaphth-1-yl)-6-methoxypyrimidine hydrochloride, m.p. 191.3-191.6°C;
- 6-tert-butyl-4-(4-fluoronaphth-1-yl)-2-methylamino-pyrimidine, m.p. 129.4-130.0°C;
- 20 2-benzylamino-6-tert-butyl-4-(4-fluoronaphth-1-yl)-pyrimidine, m.p. 106.2-106.9°C;
- 6-tert-butyl-4-(4-fluoronaphth-1-yl)-2-isopropylamino-pyrimidine hydrobromide, m.p. 196.5-197.2°C;
- 6-tert-butyl-4-(4-fluoronaphth-1-yl)-2-(2-methoxy-
- 25 ethyl)amino-pyrimidine hydrochloride, m.p. 114.5-117.8°C;
- 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(pyridin-4-yl)methylamino-pyrimidine, m.p. 149.1-149.5°C;
- 2-(2-amino)ethylamino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine fumarate, m.p. 172.4-172.6°C;
- 30 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-(4-methoxy-phenyl)methylamino-pyrimidine hydrochloride, m.p. 65-67°C;
- 4-(4-fluoronaphth-1-yl)-2-(tetrahydro-2-furyl)methylamino-6-isopropyl-pyrimidine sodium, m.p. 72.7-73.8°C;
- 4-(4-fluoronaphth-1-yl)-2-(2-hydroxy)ethylamino-6-
- 35 isopropyl-pyrimidine maleate, m.p. 101.9-104.1°C;

- 75 -

- 4-(4-fluoronaphth-1-yl)-2-(2-hydroxyethoxy)ethylamino-6-isopropyl-pyrimidine hydrobromide, m.p. 115.3-116.7°C;
2-(1,3-dihydroxyprop-2-yl)amino-4-(4-fluoronaphth-1-yl)-6-isopropyl-pyrimidine maleate, m.p. 125.3-126.6°C;
5 2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methoxy)ethyl-pyrimidine maleate, m.p. 94-100°C;
2-amino-4-(4-fluoronaphth-1-yl)-6-phenethylpyrimidine maleate, m.p. 145-146°C; and
4-(4-fluoronaphth-1-yl)-2-(2-hydroxy)ethylamino-6-
10 isopropylpyrimidine bromide.

C. Similarly, optionally replacing ethylamine with other amines of formula NHR^4R^5 and optionally replacing 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonylpyrimidine
15 with other compounds of formula (18), and following the procedures of Example 8A above, other compounds of formula I are prepared.

D. Alternative Preparation of I where R^1 is Isopropyl, R^2 is Hydrogen,
20

R^3 is Naphth-1-yl, R^4 is Phenyl and R^5 is Hydrogen

Compounds of formula I are alternatively prepared by the treatment of 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-methylsulfonylpyrimidine with aniline in the absence of
25 solvent at a higher temperatures of 120°C to afford 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-phenylaminopyrimidine, m.p. 85.7-86.3°C.

EXAMPLE 9

30 Preparation of an N-oxide of a Compound of Formula I

A. Preparation of The N-Oxide of a Compound of Formula I where R^1 is Methyl, R^2 is Hydrogen, R^3 is Naphth-1-yl, and R^4 and R^5 are Hydrogen

35 2-Amino-6-methyl-4-(naphth-1-yl)-pyrimidine (0.28 g) was dissolved in 15 ml of chloroform at 0°C. m-Chloroper-

- 76 -

benzoic acid (0.54 g) was added to the solution in portions over 5 minutes. After complete addition, the solution was warmed to 40°C for 30 minutes. The solution was washed with 10% aqueous sodium thiosulfate, 1M sodium hydroxide, and
5 water. The chloroform layer was dried (sodium sulfate) and concentrated; the solid residue was recrystallized from ethyl alcohol-diethyl ether to give 2-amino-6-methyl-4-(naphth-1-yl)-pyrimidine-1-N-oxide (0.07 g),
m.p. 228.7-229.5°C.

10

B. Similarly, replacing 2-amino-6-methyl-6-(naphth-1-yl)-pyrimidine with other compounds of formula I, and following the procedures of Example 9A above, the following N-oxides of compounds of formula I were prepared:

15 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-3-N-oxide, m.p. 188-189°C;

2-amino-6-tert-butyl-4-(4-fluoronaphth-1-yl)-pyrimidine-3-N-oxide, m.p. 188.6-190.9°C;

20 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide hydrochloride, m.p. 207-208°C;

2,6-diamino-4-(naphth-1-yl)-pyrimidine-1-N-oxide, m.p. 254.1-255.5°C;

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide, m.p. 153-155°C;

25 2-acetylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-1-N-oxide, ¹HNMR (200 MHz), J 1.39 (d, 6h), 2.51(s, 3H), 3.81(m, 1H), 7.21-7.27(m, 2H), 7.62-7.68(m, 3H), 8.10-8.23(m, 1H), 8.38-8.41(m, 1H);

2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-30 3-N-oxide, m.p. 188-189°C; and

4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-2-methylamino-1-N-oxide, m.p. 181-182.5°C.

C. Similarly, replacing 2-amino-6-methyl-4-(naphth-1-yl)-
35 pyrimidine with other compounds of formula I and following

- 77 -

the procedures of Example 9A above, other N-oxides of compounds of formula I are prepared.

EXAMPLE 10

5 Preparation of a Compound of Formula I where R¹ is Hydroxyalkyl or Alkenyl

10 A. Preparation of I where R¹ is 1-Hydroxy-1-methylethyl or Isopropenyl, R² is Hydrogen, R³ is Naphth-1-yl, and R⁴ and R⁵ are Hydrogen

Trifluoroacetic anhydride (0.211 ml, 1.50 mmol) was added to a solution of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-3-N-oxide (0.148 g, 0.498 mmol) in methylene chloride (5 ml) at room temperature. The mixture
15 was stirred for 48 hours at room temperature and then poured into 1N aqueous sodium hydroxide. The organic layer was removed, concentrated in vacuo, purified by preparative thin layer chromatography to give a mixture of 2-amino-4-(4-fluoronaphth-1-yl)-6-(1-hydroxy-1-methylethyl)-pyrimidine
20 (0.043 g, 29%), m.p. 181-184°C; and 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropenylpyrimidine (0.051 g, 36%), m.p. 138-140°C.

25 B. Similarly, replacing 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine-3-N-oxide with other N-oxides of compounds of formula I and following the procedures of Example 10A above, other compounds of formula I where R¹ is hydroxyalkyl or alkenyl are prepared.

EXAMPLE 11Preparation of a Compound of Formula I from Other Compounds of Formula I

- 5 A. Preparation of a Compound of Formula I where R⁴ is acetyl, and R⁵ is Hydrogen

2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (0.5 g) was dissolved in acetic anhydride (10 ml) and 4-dimethylaminopyridine (0.125 g) was added. The reaction mixture was stirred overnight at room temperature, then heated at 75° to 80°C for a total of 4 hours, and evaporated to dryness under vacuum. The residue was partitioned between water and ethyl acetate and then dried over magnesium sulfate. The diacetyl compound was isolated as an oil by evaporation and then dissolved in methanol (20 ml). The solution was treated with saturated sodium bicarbonate solution (2 ml) and allowed to stir overnight. The resulting monoacetyl derivative was isolated by evaporation to dryness and thorough drying under vacuum. The residue was taken up in boiling hexane and decanted from a small amount of insoluble residue and crystallized to yield 2-acetylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, m.p. 115.4-116.7°C.

- 25 B. Preparation of a Compound of Formula I where R⁴ and R⁵ are Methanesulfonyl

2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (0.374 g) was dissolved in dichloromethane (25 ml) and cooled to 0°C. Triethyl amine (0.5 ml) was added to the solution and methanesulfonyl chloride (0.12 ml) in dichloromethane (5 ml) was added dropwise. After stirring the mixture for 15 minutes, another portion of triethyl amine (0.25 ml) and methanesulfonyl chloride (0.12 ml) were added sequentially. After 15 minutes, the process was repeated and tlc examination showed a single new product. The reaction mixture was evaporated to dryness and purified by

silica gel chromatography, eluting with 1:9 ethyl acetate:hexane mixture. The colorless crystalline material was recrystallized from hexane-ether to afford 2-(bis-methanesulfonyl)amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, (354 mg, m.p. 143.8-144.2°C).

C. Preparation of a Compound of Formula I where R⁴ is Methanesulfonyl and R⁵ is Hydrogen

The 2-(bismethanesulfonyl)amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine product from Example 10B above (0.204 g) was dissolved in methanol (5 ml) and treated at room temperature with 2.5N sodium hydroxide solution (0.2 ml). The reaction mixture was stirred at room temperature for 1 hour. The mixture was partitioned between 1N hydrochloric acid and ethyl acetate. The organic layer was dried over magnesium sulfate and evaporated to dryness and recrystallized from hexane-ether to afford 2-(methanesulfonyl)amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine as a crystalline material, m.p. 276-276.9°C (prior decomposition at 273°C).

D. Preparation of a Compound of Formula I where R⁴ is Phenylaminocarbonyl, and R⁵ is Hydrogen

2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (288.3 mg) was dissolved in benzene (50 ml) and phenylisocyanate (119.1 mg) was added. The reaction mixture was heated to reflux for 48 hours, and the solvent was removed under vacuum. The residue was chromatographed on silica gel, eluting with 80:20 hexane:ethyl acetate, to yield 4-(4-fluoronaphth-1-yl)-6-isopropyl-2-phenylureido-pyrimidine (49.1 mg, m.p. 117-178).

- 80 -

EXAMPLE 11

This example illustrates the preparation of a representative pharmaceutical formulation for oral administration containing an active compound of formula I, e.g., 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

Ingredients	Quantity per tablet, mgs.
10 Active Compound	200
Lactose, spray-dried	148
Magnesium stearate	2

The above ingredients are mixed and introduced into a hard-shell gelatin capsule.

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 12

This example illustrates the preparation of another representative pharmaceutical formulation for oral administration containing an active compound of formula I, e.g., 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

Ingredients	Quantity per tablet, mgs.
30 Active Compound	400
Cornstarch	50
Lactose	145
Magnesium stearate	5

35

- 81 -

The above ingredients are mixed intimately and pressed into single scored tablets.

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 13

10

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of formula I, e.g., 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

15

An oral suspension is prepared having the following composition.

Ingredients

20	Active Compound	1.0	g
	Fumaric acid	0.5	g
	Sodium chloride	2.0	g
	Methyl paraben	0.1	g
	Granulated sugar	25.5	g
25	Sorbitol (70% solution)	12.85	g
	Veegum K (Vanderbilt Co.)	1.0	g
	Flavoring	0.035	ml
	Colorings	0.5	mg
	Distilled water	q.s. to 100	ml

30

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the orally administrable formulations of this example.

35

EXAMPLE 14

This example illustrates the preparation of a representative pharmaceutical formulation for oral administration containing an active compound of formula I, e.g., 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

An injectable preparation buffered to a pH of 4 is prepared having the following composition:

<u>Ingredients</u>		
	Active Compound	0.2 g
	Sodium Acetate Buffer Solution (0.4 M)	2.0 ml
15	HCl (1N)	q.s. to pH 4
	<u>Water (distilled, sterile)</u>	<u>q.s. to 20 ml</u>

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the injectable formulations of this example.

EXAMPLE 15

This example illustrates the preparation of a representative pharmaceutical formulation for topical application containing an active compound of formula I, e.g., 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

<u>Ingredients</u>		<u>grams</u>
	Active compound	0.2-10
	Span 60	2
	Tween 60	2
	Mineral oil	5
35	Petrolatum	10
	Methyl paraben	0.15

- 83 -

Propyl paraben	0.05
BHA (butylated hydroxy anisole)	0.01
Water	q.s. to 100

5 All of the above ingredients, except water, are combined and heated to 60°C with stirring. A sufficient quantity of water at 60°C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. 100 g.

10

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the topical formulations of this example.

15

EXAMPLE 16

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of formula I, e.g., 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine.

A suppository totalling 2.5 grams is prepared having the following composition:

25

Ingredients

Active Compound	500 mg .
Witepsol H-15*	balance

(* triglycerides of saturated vegetable fatty acid; a product of Riches-Nelson, Inc., New York, N.Y.)

30

Other compounds of formula I, such as those prepared in accordance with Examples 1-10, can be used as the active compound in the preparation of the suppository formulations of this example.

35

- 84 -

EXAMPLE 17Cloned Rat 5-HT_{2B} Receptor Binding Assay

The following describes an *in vitro* binding assay
5 utilizing cloned 5-HT_{2B} receptors radiolabelled with [³H]-
5HT.

Mouse NIH3T3 fibroblasts expressing cloned 5-HT_{2B}
receptor were maintained in Dulbecco's Modified Eagle medium
10 with 10% Fetal Calf Serum and 250 µg/ml G418 in 95/5%
O₂/CO₂. The cells were harvested using 2 mM EDTA in
phosphate buffered saline (calcium/magnesium free) and
centrifuged (500 g). The cell pellet was homogenized using
a Polytron P10 disrupter (setting 5, 5 sec) in
15 homogenization buffer (Tris, 50 mM; Na₂EDTA, 5 mM) and the
homogenate was centrifuged at 19,500 rpm using a
Sorvall/Dupont RC5C centrifuge with an SS34 rotor
(30,000-48,000 g, 15 minutes). The pellet was homogenized
(setting 5, 5 sec) in homogenization buffer and the
20 homogenate was centrifuged (30,000-48,000 g, 15 minutes).
The pellet was homogenized (setting 5, 5 sec) in
resuspension buffer (Tris, 50 mM; EDTA 0.5 mM) and the
homogenate was centrifuged (30,000-48,000 g, 15 minutes).
The pellet was homogenized (setting 5, 5 sec) in a small
25 volume of resuspension buffer to give approximately
1.5x10⁸ cells/ml. The membranes were separated into 1 ml
aliquots and stored at -70°C.

The membranes were thawed at room temperature and
30 diluted with assay buffer (calcium chloride 2H₂O, 4.5 mM;
Tris, 50 mM; 0.1% ascorbic acid). Specific binding is at
least 90% of total binding with 1.5x10⁶ cells per assay
tube. The membranes were homogenized (setting 5, 5 sec) and
then the homogenate was added to assay tubes containing
35 [³H]-5HT (2x10⁻¹⁰M) test compound (1x10⁻¹⁰-1x10⁻⁴M) and
assay buffer (q.s. to 500 µl). The assay mixture was

- 85 -

incubated at 40°C for 2 hours and then filtered over
0.1% polyethyleneimine pre-treated glass fiber filtermats
using a Brandel cell harvester. The assay tubes were rinsed
with cold assay buffer and dried by drawing air over the
5 filter for 10 seconds. Radioactivity retained on the
filters was determined by liquid scintillation counting.
For each compound tested the concentration producing 50%
inhibition of binding (IC₅₀) was determined using iterative
curve fitting techniques.

10

Proceeding as in Example 17, compounds of the invention
were found to have affinity for the 5-HT_{2B} receptor.

EXAMPLE 18

15

5-HT_{2A} 5-HT_{2B} 5-HT_{2C} Receptor Binding Methods

The following describes receptor binding methods in
which ligands with high affinity for 5-HT_{2B} receptors were
counter screened at 5-HT_{2A} and 5-HT_{2C} receptors to
20 demonstrate selectivity.

5-HT_{2A} receptors were labelled with [³H]ketanserin in
human cortex, in Cos-7 cells expressing a cloned human 5-
HT_{2A} receptor and in NIH-3T3 cells expressing the rat 5-HT_{2A}
25 receptor. For competition binding studies the ligand
concentration was approximately 0.1 nM. For saturation
binding studies concentrations of radioligand ranged from
0.01 nM to 2.0 nM. Assays were conducted in 0.5 ml of assay
buffer containing 50 mM Tris-HCl, 4 mM calcium chloride, and
30 0.1% ascorbic acid (pH 7.4 at 4°C). Non-specific binding was
defined with 10 mM unlabelled ketanserin. After a 60 minute
incubation at 32°C, membranes were harvested onto filters
treated with 0.1% polyethylenimine and the bound
radioactivity was determined.

35

Human 5-HT_{2B} receptors were labelled in Cos-7 cells as described above except that the radioligand was [³H]5-HT and that the assay buffer contained 10 mM pargyline and 0.1% ascorbic acid. For competition binding studies the
5 radioligand concentration was approximately 0.4 nM while for saturation binding studies the concentration of [³H]5-HT ranged from 0.05 to 8 nM. Non-specific binding was defined with 10 mM 5-HT. Incubations were for 120 minutes at 4°C.

10 5-HT_{2C} receptors were labelled in choroid plexus, Cos-7 cells expressing the human 5-HT_{2C} receptor and in NIH-3T3 expressing the rat 5-HT_{2C} receptor. Assays were conducted as described for the 5-HT_{2A} receptor except that the radioligand was [³H]mesulergine. The radioligand
15 concentration for competition studies was approximately 0.2 nM while for saturation binding studies the concentration ranged from 0.1 to 18 nM. Non-specific binding was defined with 10 µM unlabelled mesulergine.

20 Competition radioligand binding data was analyzed using a four parameter logistic equation and iterative curve-fitting techniques to obtain estimates of the IC₅₀ and Hill slope. K_d values, determined from saturation binding studies were then used to calculate inhibition dissociation
25 constants (K_i).

Proceeding as in Example 18, compounds of the invention were found to have affinity for the 5-HT_{2B} receptor.

30

EXAMPLE 19

5-HT_{2B} Receptor Tissue Based Functional Assay

The following describes an in vitro functional assay characterizing 5-HT receptors (the putative 5-HT_{2B}) in rat
35 stomach fundus longitudinal muscle.

The rat stomach fundus was set up as described by Baxter et al., (1994), *Brit. J. Pharmacol.*, 112, 323-331. Strips of longitudinal muscle were obtained from the stomach fundus of male Sprague Dawley rats. The mucosa was removed
5 and the strips were suspended with a resting tension of 1 gram in oxygenated Tyrode solution. The temperature was maintained at 37°C, and the experiments were conducted in the presence of pargyline (100 µM).

10 To test for antagonist actions concentration-response curves to 5-HT were generated in the presence or absence of the putative antagonist. Schild plots were generated to determine the affinity of the antagonist. To test for agonist the actions of the test compound alone, on the
15 isolated tissue strip were quantified.

The compounds of the present invention were found to be antagonists at the 5-HT_{2B} receptor when tested by this method.

20

EXAMPLE 20

Anxiolytic Behavior Assay

The following describes an in vivo method for
25 determining anxiolytic activity by measuring the extent the drug affects the natural anxiety of mice when exposed to a novel, brightly lighted environment.

Naive male C5BI/6J mice, 18-20 g, are kept in groups of
30 10 mice in quarters controlled for sound, temperature and humidity. Food and water are available ad libitum. The mice are kept on a 12 hour light and 12 hour dark cycle, with lights on at 6:00 a.m. and off at 6:00 p.m. All experiments begin at least 7 days after arrival on site.

35

- 88 -

The automated apparatus for detecting changes in exploration is obtained from Omni-Tech Electronics Columbus Ohio and is similar to that of Crawley and Goodwin (1980), as described in Kilfoil et al., cited previously. Briefly, the chamber consists of a plexiglass box (44 x 21 x 21 cm), divided into two chambers by a black plexiglass partition. The partition dividing the two chambers contains a 13 x 5 cm opening through which the mouse can easily pass. The dark chamber has clear sides and a white floor. A fluorescent tube light (40 watt) placed above the chambers provides the only illumination. The Digiscan Animal Activity Monitor System RXYZCM16 (Omni-Tech Electronics) records the exploratory activity of the mice within the test chambers.

Prior to commencement of the study the mice are given 60 min to acclimatize to the laboratory environment. After a mouse receives an intraperitoneal (i.p.) injection of either test compound or vehicle it is returned to its home cage for a 15 min post-treatment period. The mouse is then placed in the center of the light chamber and monitored for 10 minutes.

Anxiolysis is seen as a general increase in exploratory activity in the lighted area. An increase in exploratory activity is reflected by increased latency (the time for the mouse to move to the dark chamber when first placed in the center of the lighted area), increase in shuttle activity, increased or unaltered locomotor activity (number of grid lines crossed) and decreased time spent in the dark compartment.

The compounds of the present invention ameliorate anxiolytic behavior when tested by this method.

- 89 -

EXAMPLE 21Withdrawal Anxiety Assay

The following describes an *in vivo* procedure for
5 determining amelioration of the symptoms caused by
Withdrawal from addictive substances by measuring the extent
the drug affects the anxiety that occurs in mice after
chronically treating with an addictive substance and then
abruptly ceasing the treatments.

10

Naive male BKW mice (25-30 g) are caged in groups of
ten in quarters controlled for sound, temperature and
humidity. Food and water are available *ad libitum*. The
mice are kept on a 12 hour light cycle and 12 hour dark
15 cycle, with lights on at 6:00 a.m. and off at 6:00 p.m. All
experiments begin at least 7 days after arrival on site.

Levels of anxiety are determined by the two-compartment
exploratory model of Crawley and Goodwin (see Example 14).
20 Anxiolysis is seen as a general increase in exploratory
activity in the lighted area. An increase in exploratory
activity is reflected by increased latency (the time for the
mouse to move to the dark chamber when first placed in the
center of the lighted area), increased or unaltered
25 locomotor activity (number of grid lines crossed), increased
number of rears and decreased time spent in the dark
compartment.

Increased exploratory activity in the lighted area is
30 induced by treating the mice for 14 days with ethanol (8.0 %
w/v in drinking water), nicotine (0.1 mg/kg, *i.p.*, twice
daily) or cocaine (1.0 mg/kg, *i.p.*, twice daily).
Anxiolysis is assessed 1, 3, 7 and 14 days after
commencement of the drug regime. The treatment is abruptly
35 ceased and exploratory activity in the lighted area is
determined 8, 24 and 48 hours thereafter. Vehicle or test


compounds are administered during the withdrawal phase by intraperitoneal injection. Responses are represented as inhibition of the decrease in anxiolytic behavior after the ethanol, cocaine or nicotine treatment is ceased.

5

The compounds of the present invention show amelioration of the symptoms caused by withdrawal from addictive substances when tested by this method.

Claims

1. A compound of the formula:



wherein:

R^1 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl, optionally substituted phenyl, optionally substituted phenyl lower alkyl, $-NR^6R^7$, $-CO_2R^8$, or $-O(CH_2)_nR^9$, in which

n is 1, 2, or 3;

R^6 and R^7 are hydrogen or lower alkyl;

R^8 is hydrogen or lower alkyl; and

R^9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;

R^2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl;

R^3 is optionally substituted aryl;

R^4 is hydrogen, lower alkyl, optionally substituted phenyl-lower alkyl, hydroxy lower alkyl, acyl, $-(CH_2)_mNR^6R^7$, or $-SO_2R^{10}$; in which

m is an integer of 1-6;

R^6 and R^7 are hydrogen or lower alkyl, and

R^{10} is lower alkyl; and

R^5 is hydrogen or lower alkyl;

provided that:

when R^3 is naphthyl, pyridyl, thienyl, indol-1-yl,

2,3-dihydroindol-1-yl, or furanyl, and R^2 , R^4 and

R^5 are all hydrogen, R^1 is not methyl;

35

when R^3 is phenyl or naphthyl, R^1 is not $-NR^6R^7$;
when R^3 is naphthyl, R^1 is not phenyl; and
when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5 are
hydrogen;

5 or a pharmaceutically acceptable salt or N-oxide thereof.

2. The compound of Claim 1, wherein R^4 and R^5 are
hydrogen or lower alkyl.

10 3. The compound of Claim 2, wherein R^1 is lower
alkyl, fluoroalkyl, or hydroxyalkyl, and R^3 is optionally
substituted 1-naphthyl, or a pharmaceutically acceptable
salt or N-oxide thereof.

15 4. The compound of Claim 3, wherein R^1 is methyl,
 R^2 , R^4 , and R^5 are hydrogen, and R^3 is 2-methylnaphth-1-yl,
namely 2-amino-4-(2-methylnaphth-1-yl)-6-methylpyrimidine,
or a pharmaceutically acceptable salt or N-oxide thereof.

20 5. The compound of Claim 3, wherein R^1 is isopropyl,
 R^2 , R^4 , and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl,
namely 2-amino-4-(4-fluoronaphth-1-yl)-6-
isopropylpyrimidine, or a pharmaceutically acceptable salt
or N-oxide thereof.

25 6. The compound of Claim 5, wherein the N-oxide is
at the 1-position, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-
isopropylpyrimidine-1-N-oxide.

30 7. The compound of Claim 3, wherein R^1 is 1-fluoro-
1-methylethyl, R^2 , R^4 , and R^5 are hydrogen, and R^3 is 4-
fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-
(1-fluoro-1-methylethyl)-pyrimidine, or a pharmaceutically
acceptable salt or N-oxide thereof.

35

8. The compound of Claim 3, wherein R^1 is 1-hydroxy-1-methylethyl, R^2 , R^4 , and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(1-hydroxy-1-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

9. The compound of Claim 3, wherein R^1 is 1-fluoro-1-methylethyl, R^2 , R^4 , and R^5 are hydrogen, and R^3 is 4,6-difluoronaphth-1-yl, namely 2-amino-4-(4,6-difluoronaphth-1-yl)-6-(1-fluoro-1-methylethyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

10. The compound of Claim 3, wherein R^1 is isopropyl, R^2 and R^4 are hydrogen, R^5 is methyl, and R^3 is 4-fluoronaphth-1-yl, namely 2-methylamino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

11. The compound of Claim 3, wherein R^1 is 2-methylpropyl, R^2 , R^4 , and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-4-(4-fluoronaphth-1-yl)-6-(2-methylpropyl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

12. The compound of Claim 3, wherein R^1 is tert-butyl, R^2 , R^4 , and R^5 are hydrogen, and R^3 is 4-fluoronaphth-1-yl, namely 2-amino-6-(tert-butyl)-4-(4-fluoronaphth-1-yl)-pyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

13. The compound of Claim 2, wherein R^1 is lower alkyl and R^3 is optionally substituted indole, or a pharmaceutically acceptable salt or N-oxide thereof.


14. The compound of Claim 13, wherein R^1 is methyl, R^2 , R^4 , and R^5 are hydrogen, and R^3 is indol-4-yl, namely

- 94 -

2-amino-4-(1H-indol-4-yl)-6-methylpyrimidine, or a pharmaceutically acceptable salt or N-oxide thereof.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of Claims 1 to 14 in admixture with one or more pharmaceutically acceptable non-toxic carriers.

16. A process for preparing a compound of the formula I :



wherein:

R¹ is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl, optionally substituted phenyl, optionally substituted phenyl lower alkyl, -NR⁶R⁷, -CO₂R⁸, or -O(CH₂)_nR⁹, in which
 n is 1, 2, or 3;
 R⁶ and R⁷ are hydrogen or lower alkyl;
 R⁸ is hydrogen or lower alkyl; and
 R⁹ is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;
 R² is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl;
 R³ is optionally substituted aryl;
 R⁴ is hydrogen, lower alkyl, optionally substituted phenyl-lower alkyl, hydroxy lower alkyl, acyl, -(CH₂)_mNR⁶R⁷, or -SO₂R¹⁰; in which
 m is an integer of 1-6;
 and

- 95 -


R^{10} is lower alkyl; and
 R^5 is hydrogen or lower alkyl;
 provided that:

- when R^3 is naphthyl, pyridyl, thienyl, indol-1-yl,
 5 2,3-dihydroindol-1-yl, or furanyl, and R^3 , R^4
 and R^5 are all hydrogen, R^1 is not methyl;
 when R^3 is phenyl or naphthyl, R^1 is not $-NR^6R^7$;
 when R^3 is naphthyl, R^1 is not phenyl; and
 10 when R^3 is 1,2,3,4-tetrahydroquinolinyl, R^4 and R^5
 are hydrogen;

and the pharmaceutically acceptable salts and N-oxides
 thereof; which process comprises:

- (a) reacting a compound of formula (4):

15




20

- where R^1 and R^2 are as defined with respect to formula I,
 and R^4 and R^5 are hydrogen or lower alkyl with a boronic
 acid derivative of formula (5), i.e., $R^3B(OH)_2$ where R^3 is
 25 as defined with respt of formula I, to form a compound of
 formula I where R^1 , R^2 and R^3 are as defined, and R^4 and R^5
 are hydrogen or lower alkyl; or

- (b) reacting a compound of formula (4):

30




35

- 96 -

where R^1 and R^2 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl with a boron complex of formula (7), i.e., $R^3B(OCH_3)_2$ where R^3 is as defined with respect to formula I to form a compound of formula I where
 5 R^1 , R^2 and R^3 are as defined and R^4 and R^5 are hydrogen or lower alkyl; or

(c) reacting a compound of formula (4):




15 where R^1 and R^2 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl with a compound of formula (8):



where Y is CH_2 , O, S or NH, and n is 0, 1 or 2, to form a compound of formula I where R^1 and R^2 , are as defined, R^3 is a bicyclic ring system containing N as a point of attachment to the pyrimidine nucleus, and R^4 and R^5 are hydrogen or lower alkyl; or


(d) reacting a compound of formula (11):



where R^1 , R^2 and R^3 are as defined with a compound of formula (2) i.e., $NH_2C(:NH)NR^4R^5$ where R^4 and R^5 are as
 35 defined with respect to formula I to form a compound of formula I where R^1 , R^2 , R^3 , R^4 and R^5 are as defined; or

- 97 -

(e) reacting a compound of formula (13):




where R^2 and R^3 are as defined with respect to formula I

with a compound of formula (2) i.e., $\text{NH}_2\text{C}(:\text{NH})\text{NR}^4\text{R}^5$ where R^4

10 and R^5 are as defined with respect to formula I to form a compound of formula I where R^1 is hydrogen, and R^2 , R^3 , R^4 and R^5 are as defined; or


(f) reacting a compound of formula (19):



where R^2 and R^3 are as defined with a compound of formula

20 (2) i.e., $\text{NH}_2\text{C}(:\text{NH})\text{NR}^4\text{R}^5$, to form a compound of formula I where R^1 is SCH_3 , and R^2 , R^3 , R^4 and R^5 are as defined; or

(g) reacting a compound of formula I where R^1 is chloro:




30 where R^2 and R^3 are as defined with respect to formula I and R^4 and R^5 are hydrogen or lower alkyl with

i) a reducing agent to give a compound of formula I where R^1 is hydrogen, R^2 and R^3 are as defined and R^4 and R^5 are hydrogen or lower alkyl; or

35 ii) a secondary amine of formula HNR^6R^7 , where R^6 and R^7 are as defined with respect to formula I to

form a compound of formula I where R^1 is $-NR^6R^7$,
and R^2 and R^3 are as defined and R^4 and R^5 are
hydrogen or lower alkyl; or

- 5 (h) reacting a compound of the formula:



10

where R^1 , R^2 and R^3 are as defined with respect to formula I
with a secondary amine of formula HNR^4R^5 , where R^4 and R^5
are as defined with respect to formula I to form a compound
of formula I, where R^1 , R^2 , R^3 , R^4 and R^5 are as defined; or

15

- (i) reacting an N-oxide of a compound of formula I where R^1
is alkyl with a carboxylic anhydride to give a compound of
formula I where R^1 is hydroxyalkyl or alkenyl; and
optionally followed by

20

- (j) reacting a compound of formula I with an oxidizing
agent to give an N-oxide of a compound of formula I; or

- (k) reacting a compound of formula I with a strong acid to
25 give a pharmaceutically acceptable salt of a compound of
formula I.

30

17. A compound as claimed in any one of claims 1 to
14 whenever prepared by the process of claim 16.

18. A compound as claimed in any one of claims 1 to
14 as a therapeutic agent.

19. The use of a compound as claimed in any one of
35 claims 1 to 14 for the preparation of a medicament for the
treatment of a disease state selected from the group:

- 99 -

generalized anxiety disorder, panic disorder, obsessive compulsive disorder, alcoholism, depression, migraine, hypertension, sleep disorders, anorexia nervosa, and priapism.

5

20. The invention as hereinbefore described.

21. A method for treating a mammal having a disease state which is alleviable by treatment with a 5HT_{2B} antagonist, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound as claimed in any one of claims 1 to 14.

10

15

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/02454

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D239/42 C07D239/46 C07D401/04 C07D403/04 C07D405/04
A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PHARMAZIE, vol. 49, no. 11, 1994, pages 801-6, XP002037178 J. L. MOKROSZ ET AL.: "Structure-activity relationship studies of CNS agents. Part 14: Structural requirements for the 5-HT1A and 5-HT2A receptor selectivity of simple 1-(2-pyrimidinyl)piperazine derivatives" see page 802, right-hand column, compounds 28-30; page 803, table 2; page 804, table 3 ---	1,2,18
X	EP 0 210 044 A (PFIZER INC.) 28 January 1987 see claims 1-4,11; example 21 ---	1,2,18
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

7 August 1997

Date of mailing of the international search report

21.08.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/02454

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 85 00603 A (STERLING DRUG INC.) 14 February 1985 see page 9, line 26 - page 10, line 7 ---	1,2
X	WO 85 00604 A (STERLING DRUG INC.) 14 February 1985 see page 11, line 24 - page 12, line 9 ---	1,2
X	WO 86 04583 A (THE UPJOHN CO.) 14 August 1986 see page 19, line 15 - page 20, line 35 ---	1,2
X	WO 89 07599 A (GEORGIA STATE UNIVERSITY FOUNDATION, INC.) 24 August 1989 see page 25, formula below line 4 see claim 24 ---	1
X	WO 89 11279 A (GEORGIA STATE UNIVERSITY FOUNDATION, INC.) 30 November 1989 see page 23, table VI ---	1
X	US 3 965 101 A (H. L. YALE ET AL.) 22 June 1976 see column 11, example no. 5, starting compound; column 13, example no. 9, starting compound ---	1,2
X	EP 0 521 471 A (SHIONOGI SEIYAKU K. K.) 7 January 1993 see page 9, compound 4 ---	1
X	DE 19 21 049 A (SANDOZ AG) 6 November 1969 see example 2 ---	1
X	DE 30 29 871 A (G. D. SEARLE & CO.) 26 February 1981 see page 8, formula; page 13, formula ---	1,2
X	DE 27 50 288 A (DR. K. THOMAE GMBH) 17 May 1979 see page 21, starting material for compound p ---	1,2
X	DE 42 37 768 A (CIBA-GEIGY AG) 13 May 1993 see page 9, line 20 - line 45 ---	1,2
P,X	WO 96 32384 A (TAIHO PHARMACEUTICAL CO., LTD.) 17 October 1996 see pages 53-57, compounds 1-20; pages 58- 60, compounds 24-32; pages 61-64, compounds 34-44 ---	1,2
3 P,X	WO 96 39400 A (NEUROCRINE BIOSCIENCES, INC.) 12 December 1996 see claim 2 ---	2

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/02454

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF ORGANIC CHEMISTRY, vol. 25, 1960, pages 647-8, XP002037179 R. P. MARIELLA ET AL.: "Preparation of Various Substituted Pyrimidines" cited in the application see tables I,II ---	1,2
X	EGYPTIAN JOURNAL OF CHEMISTRY, vol. 37, no. 4, 1994, pages 423-31, XP002037180 S. A. ESSAWY ET AL.: "Synthesis and Reactions of 2-Amino-4-Aryl-6-(2'-Methoxynaphthyl) Pyrimidines" cited in the application see page 430, formula (I) ---	1,2
A	EP 0 459 830 A (THE WELLCOME FOUNDATION LTD.) 4 December 1991 cited in the application see claims 1-8 ---	1,2,15, 18,19
A	DE 22 55 525 A (BASF AG) 22 May 1974 see page 19, line 6, compound 2,4-diamino-6-phenyl-pyrimidine ---	1
A	COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol. 26, 1961, pages 2865-70, XP002037181 Z. BUDESINSKY ET AL.: "Über die Darstellung von 2-Sulfanilamido- 4-methylpyrimidinen mit einem heterocyclischen Substituenten in 6-Stellung" cited in the application see page 2865, compounds IIa - IIe ---	1,2
A	EP 0 114 770 A (SANOFI, S. A.) 1 August 1984 see page 14 ---	1
A	IZV. SIB. OTD. AKAD. NAUK SSSR, SER. KHIM. . NAUK, vol. 4, 1990, pages 27-31, XP002037182 O. A. ZAGULAYEVA ET AL.: "Synthesis of methoxyalkylsubstituted 2-aminopyrimidines from gamma-methoxyalkynylketones" cited in the application see page 27, compounds of formula II --- -/--	1,2

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/02454

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 147 876 A (A. MIZUCHI ET AL.) 15 September 1992 cited in the application see claims 1,5 ---	1,15
A	PHARMACOLOGICAL REVIEWS, vol. 46, no. 2, 1994, pages 157-203, XP000602868 D. HOYER ET AL.: "VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin)" cited in the application see pages 176-177, chapter C ---	
A	NEUROPHARMACOLOGY, vol. 33, no. 3/4, 1994, pages 261-73, XP002037183 G. R. MARTIN ET AL.: "Classification Review. Receptors for 5-Hydroxytryptamine: Current Perspectives on Classification and Nomenclature" cited in the application see page 265, right-hand column, paragraph "5-HT2B receptors" -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 97/02454

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 21
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/02454

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 210044 A	28-01-87	US 4711888 A	08-12-87
		AU 569194 B	21-01-88
		AU 6044786 A	30-04-87
		CA 1265519 A	06-02-90
		CN 1006792 B	14-02-90
		EG 18181 A	30-09-92
		IE 63404 B	19-04-95
		JP 6047579 B	22-06-94
		JP 62026276 A	04-02-87
		NO 173442 C	15-12-93
		SU 1574171 A	23-06-90

WO 8500603 A	14-02-85	US 4504482 A	12-03-85
		AU 3154184 A	04-03-85
		EP 0150205 A	07-08-85
		JP 60502003 T	21-11-85

WO 8500604 A	14-02-85	US 4512993 A	23-04-85
		AU 561765 B	14-05-87
		AU 3153084 A	04-03-85
		EP 0150206 A	07-08-85
		JP 60501952 T	14-11-85

WO 8604583 A	14-08-86	EP 0210228 A	04-02-87
		JP 62501632 T	02-07-87
		US 4795812 A	03-01-89

WO 8907599 A	24-08-89	US 4929726 A	29-05-90
		AU 3192389 A	06-09-89
		US 4963676 A	16-10-90
		US 5304647 A	19-04-94

WO 8911279 A	30-11-89	AU 3752589 A	12-12-89

US 3965101 A	22-06-76	US 3886158 A	27-05-75
		CA 1051427 A	27-03-79
		DE 2435383 A	13-02-75
		FR 2238492 A	21-02-75
		GB 1476124 A	10-06-77
		JP 50041893 A	16-04-75

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/02454

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 521471 A	07-01-93	CA 2072945 A JP 5178841 A KR 9605951 B US 5260440 A	02-01-93 20-07-93 06-05-96 09-11-93
DE 1921049 A	06-11-69	AT 304554 A AT 304556 A BE 732249 A CH 507244 A CH 507959 A FR 2007556 A GB 1252953 A NL 6906566 A US 3535330 A	15-12-72 15-12-72 28-10-69 15-05-71 31-05-71 09-01-70 10-11-71 31-10-69 20-10-70
DE 3029871 A	26-02-81	AU 531507 B AU 6115380 A CA 1137084 A CA 1246063 A CA 1246064 A CH 645898 A FR 2463143 A GB 2056449 A JP 1584114 C JP 2009592 B JP 56032479 A US 4405780 A	25-08-83 12-02-81 07-12-82 06-12-88 06-12-88 31-10-84 20-02-81 18-03-81 22-10-90 02-03-90 01-04-81 20-09-83
DE 2750288 A	17-05-79	AT 361623 B AU 4144878 A CA 1107726 A EP 0001981 A JP 54076588 A US 4256738 A	25-03-81 17-05-79 25-08-81 30-05-79 19-06-79 17-03-81
DE 4237768 A	13-05-93	NONE	
WO 9632384 A	17-10-96	AU 5289296 A CA 2190973 A EP 0767170 A	30-10-96 17-10-96 09-04-97

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/02454

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9632384 A		NO 965334 A	12-02-97
WO 9639400 A	12-12-96	AU 5990496 A	24-12-96
EP 459830 A	04-12-91	AU 646669 B	03-03-94
		AU 7809891 A	05-12-91
		CA 2043671 A	02-12-91
		HU 209576 B	29-08-94
		JP 5320142 A	03-12-93
DE 2255525 A	22-05-74	AU 6228173 A	08-05-75
		BE 807257 A	13-05-74
		CH 585779 A	15-03-77
		FR 2206357 A	07-06-74
		GB 1440663 A	23-06-76
		JP 50000017 A	06-01-75
		US 4113720 A	12-09-78
EP 114770 A	01-08-84	FR 2539741 A	27-07-84
		AU 563160 B	02-07-87
		AU 2323684 A	26-07-84
		CA 1217490 A	03-02-87
		CS 8400424 A	15-08-85
		EG 16212 A	30-06-89
		JP 59137469 A	07-08-84
		OA 7638 A	23-05-85
		SU 1342415 A	30-09-87
		US 4624952 A	25-11-86
US 5147876 A	15-09-92	JP 2221275 A	04-09-90
		AT 136542 T	15-04-96
		AU 629595 B	08-10-92
		AU 4732989 A	05-07-90
		CA 2006944 A	29-06-90
		DE 68926232 D	15-05-96
		DE 68926232 T	17-10-96
		EP 0379806 A	01-08-90
		EP 0612746 A	31-08-94
		HU 210001 B	30-01-95
		US 5264435 A	23-11-93

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/02454

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5147876 A		CN 1045390 A	19-09-90
		CN 1090846 A	17-08-94
		HU 209594 B	29-08-94
		HU 209574 B	29-08-94
		JP 3014568 A	23-01-91
